Forecasts

Every forecast, sealed until the trial reads out.

Each forecast gets a fingerprint the day it is made. The fingerprint is public; the forecast stays hidden. When the trial's results are posted, the forecast is revealed, checked against its fingerprint, and scored.

The ledger

0 forecasts sealed so far. The first batch is being prepared and will cover every trial below. From then on, new forecasts are sealed every night, and none is ever edited or removed.

How scoring works → · What counts as a trial meeting its goal →

Trials we will forecast

Company-sponsored, randomized phase 2 and 3 trials that have finished enrolling and have not posted results: finished in the last six months or finishing in the next twelve (966 trials).

966 trials shown

Forecast
Apr 2026Combination Gerotherapeutic Interventions for Healthspan ImprovementNCT07475546 · Rapamycin, Naltrexone, MetforminAgelessRxOtherPhase 330Not sealed yet
Apr 2026Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and HyperuricemiaNCT06603142 · Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MGGuangzhou Ruianbo Pharmaceutical Technology Co., LtdImmunology & inflammationPhase 2/3636Not sealed yet
Apr 2026A Phase 2 Trial of JKN24011 in COPDNCT07440524 · JKN24011, PlaceboJoincare Pharmaceutical Group Industry Co., LtdRespiratoryPhase 2215Not sealed yet
Apr 2026Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and IrinotecanNCT06199973 · SHR-A1811, TAS-102, Regorafenib , FruquintinibSuzhou Suncadia Biopharmaceuticals Co., Ltd.OncologyPhase 3130Not sealed yet
Apr 1, 2026HPP737 in Adult Patients With Plaque PsoriasisNCT07712731 · HPP737, Placebo matching HPP737, ApremilastNewsoara Biopharma Co., Ltd.Immunology & inflammationPhase 3607Not sealed yet
Apr 1, 2026A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideNCT06208150 · Talquetamab, Pomalidomide, TeclistamabJanssen Research & Development, LLCOncologyPhase 3838Not sealed yet
Apr 2, 2026Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PDNCT05819359 · BIA 28-6156 10 mg, BIA 28-6156 60 mg, PlaceboBial R&D Investments, S.A.NeurologyPhase 2237Not sealed yet
Apr 2, 2026A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)NCT06172257 · Dexamethasone ophthalmic suspension (OCS-01), VehicleOculisOphthalmologyPhase 3401Not sealed yet
Apr 2, 2026Glucose Tolerance StudyNCT07412730 · TRPTI 150mg, TRPTI 300mg, PlaceboRDC Clinical Pty LtdOtherPhase 219Not sealed yet
Apr 2, 2026Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)NCT06956235 · Tulisokibart, PlaceboMerck Sharp & Dohme LLCImmunology & inflammationPhase 2149Not sealed yet
Apr 3, 2026A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult ParticipantsNCT06794866 · OnabotulinumtoxinA, PlaceboAbbVieOtherPhase 3150Not sealed yet
Apr 3, 2026Light-Activated Antimicrobial Therapy to Prevent Surgical Site InfectionsNCT06702878 · nasal antimicrobial photodisinfection therapyOndine Biomedical Inc.Infectious disease & vaccinesPhase 34,787Not sealed yet
Apr 3, 2026Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AMLNCT03250338 · Crenolanib, Cytarabine, MitoxantroneArog Pharmaceuticals, Inc.OncologyPhase 3106Not sealed yet
Apr 6, 2026Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AMLNCT03258931 · Crenolanib, Midostaurin, CytarabineArog Pharmaceuticals, Inc.OncologyPhase 3214Not sealed yet
Apr 6, 2026Reformulated PG324 Ophthalmic Solution for Intraocular Pressure ReductionNCT07082816 · Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solutionAlcon ResearchOphthalmologyPhase 3489Not sealed yet
Apr 6, 2026A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 · Retatrutide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 32,335Not sealed yet
Apr 9, 2026Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPDNCT05612035 · Frespaciguat, PlaceboMerck Sharp & Dohme LLCCardiovascularPhase 2129Not sealed yet
Apr 9, 2026A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With AcromegalyNCT07814651 · SYHX2008, Sandostatin LARCSPC ZhongQi Pharmaceutical Technology Co., Ltd.Endocrine & bonePhase 278Not sealed yet
Apr 9, 2026A Study of ONO-1110 in Patients With Major Depressive DisorderNCT06792136 · ONO-1110, PlaceboOno Pharmaceutical Co., Ltd.PsychiatryPhase 2103Not sealed yet
Apr 9, 2026A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque PsoriasisNCT04123795 · Certolizumab pegol, PlaceboUCB Biopharma SRLImmunology & inflammationPhase 349Not sealed yet
Apr 10, 2026A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)NCT05066997 · Dexamethasone ophthalmic suspension (OCS-01), VehicleOculisOphthalmologyPhase 2/3552Not sealed yet
Apr 10, 2026A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or BehaviorNCT07193901 · Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spraySichuan Purity Pharmaceutical Technology Co., Ltd.PsychiatryPhase 298Not sealed yet
Apr 10, 2026Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)NCT05153239 · Irinotecan, Lurbinectedin, IrinotecanPharmaMarOncologyPhase 3705Not sealed yet
Apr 10, 2026Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)NCT07670546 · Olokizumab, PlaceboR-Pharm International, LLCImmunology & inflammationPhase 3125Not sealed yet
Apr 10, 2026A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic DermatitisNCT07158151 · RSS0393 ointment, RSS0393 ointment, RSS0393 ointmentReistone Biopharma Company LimitedImmunology & inflammationPhase 2168Not sealed yet
Apr 10, 2026A Study of TCD601 in de Novo Renal Transplant RecipientsNCT05669001 · TCD601, belatacept, ATGITB-Med LLCKidneyPhase 276Not sealed yet
Apr 13, 2026Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)NCT03651128 · bb2121, Daratumumab, PomalidomideCelgeneOncologyPhase 3386Not sealed yet
Apr 13, 2026Phase 2 Trial of HY209gel in Atopic Dermatitis PatientsNCT06024499 · HY209GEL Active, PlaceboShaperonImmunology & inflammationPhase 2210Not sealed yet
Apr 14, 2026INcreased Sun Exposure Without Pain In Research Participants With EPP or XLPNCT06144840 · Dersimelagon, PlaceboTanabe Pharma America, Inc.PainPhase 3165Not sealed yet
Apr 14, 2026PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 MonthsNCT07333352 · 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (RZ700), 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (Prevnar 13)Reinovax Biologics Co., LTDInfectious disease & vaccinesPhase 2480Not sealed yet
Apr 14, 2026A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate VaccineNCT06615375 · Shigella4V2, PlaceboLimmaTech Biologics AGInfectious disease & vaccinesPhase 2120Not sealed yet
Apr 15, 2026Study of DM-101PX in Adults With Birch Pollen AllergyNCT07254871 · DM-101PX, PlaceboDesentum OyRespiratoryPhase 297Not sealed yet
Apr 15, 2026Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)NCT06182085 · PRI-002, PlaceboPRInnovation GmbHNeurologyPhase 2304Not sealed yet
Apr 15, 2026A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05979311 · Dolutegravir, Lamivudine, BictegravirViiV HealthcareInfectious disease & vaccinesPhase 3307Not sealed yet
Apr 16, 2026Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)NCT05270668 · Tulisokibart, Companion diagnostic ( CDx), PlaceboPrometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Immunology & inflammationPhase 2154Not sealed yet
Apr 16, 2026Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With MetforminNCT06571591 · CT-L03 Group 1, CT-L03 Group 2, PlaceboCelltrionDiabetes & obesityPhase 3606Not sealed yet
Apr 16, 2026A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 · Retatrutide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 31,946Not sealed yet
Apr 16, 2026A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)NCT05714969 · TAK-755TakedaCardiovascularPhase 229Not sealed yet
Apr 17, 2026A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal SurgeryNCT06890533 · Experimental: YZJ-4729, Placebo Comparator: Saline, Active Comparator: MorphineShanghai Haiyan Pharmaceutical Technology Co., Ltd.PainPhase 3560Not sealed yet
Apr 17, 2026Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1NCT06630286 · ISL/LEN, B/F/TAF, PTM B/F/TAFGilead SciencesInfectious disease & vaccinesPhase 3609Not sealed yet
Apr 17, 2026A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaNCT06502366 · BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFAAstraZenecaRespiratoryPhase 3424Not sealed yet
Apr 17, 2026A Trial of HRS-7535 Tablets in Subjects With Overweight or ObesityNCT06904105 · HRS-7535 Tablets, HRS-7535 Placebo TabletsShandong Suncadia Medicine Co., Ltd.Diabetes & obesityPhase 3556Not sealed yet
Apr 18, 2026A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) LesionsNCT07275723 · HRS-9231 Injection, Gadobutrol Injection, Magnetic Resonance Imaging (MRI)Shanghai Shengdi Pharmaceutical Co., LtdOtherPhase 3309Not sealed yet
Apr 20, 2026A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast CancerNCT06685796 · BEBT-209 capsules, Carboplatin injection, Gemcitabine hydrochloride for injectionBeBetter Med IncOncologyPhase 265Not sealed yet
Apr 20, 2026A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1）NCT06930612 · CM512, PlaceboBeijing Keymed Biosciences Co., Ltd.RespiratoryPhase 2120Not sealed yet
Apr 21, 2026Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)NCT06615557 · Fasedienol Nasal Spray, Placebo Nasal SprayVistaGen Therapeutics, Inc.PsychiatryPhase 3238Not sealed yet
Apr 21, 2026A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid ArthritisNCT07233655 · SHR-3045 Injection, SHR-3045 Injection PlaceboGuangdong Hengrui Pharmaceutical Co., LtdImmunology & inflammationPhase 230Not sealed yet
Apr 21, 2026A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated EosinophilsNCT06897748 · Placebo, TozorakimabAstraZenecaRespiratoryPhase 298Not sealed yet
Apr 22, 2026P3b Short-term Study of CTN in Patients With ADHD and Comorbid AnxietyNCT06973577 · Centanafadine, PlaceboOtsuka Pharmaceutical Development & Commercialization, Inc.PsychiatryPhase 3315Not sealed yet
Apr 22, 2026A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque PsoriasisNCT06973291 · Zasocitinib, Deucravacitinib, Placebo to match zasocitinibTakedaImmunology & inflammationPhase 3606Not sealed yet
Apr 22, 2026A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)NCT06812325 · VRDN-003, PlaceboViridian Therapeutics, Inc.OphthalmologyPhase 3320Not sealed yet
Apr 22, 2026Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes SubjectsNCT06688123 · SHR-3167, SHR-3167, Insulin glargineJiangsu HengRui Medicine Co., Ltd.Diabetes & obesityPhase 2275Not sealed yet
Apr 22, 2026A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187 · Cagrilintide, Semaglutide, PlaceboNovo Nordisk A/SDiabetes & obesityPhase 3300Not sealed yet
Apr 23, 2026Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic RhinitisNCT07556393 · INI-2004, PlaceboInimmune CorporationRespiratoryPhase 278Not sealed yet
Apr 23, 2026Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1NCT06630299 · ISL/LEN, Antiretroviral CombinationsGilead SciencesInfectious disease & vaccinesPhase 3600Not sealed yet
Apr 24, 2026A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With OsteoporosisNCT06804590 · 9MW0311, Prolia®Mabwell (Shanghai) Bioscience Co., Ltd.Endocrine & bonePhase 3280Not sealed yet
Apr 24, 2026Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)NCT04895358 · pembrolizumab, paclitaxel, nab-paclitaxelMerck Sharp & Dohme LLCOncologyPhase 3342Not sealed yet
Apr 24, 2026A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum DepressionNCT07096791 · KH607 tablet, placeboChengdu Kanghong Pharmaceutical Group Co., Ltd.PsychiatryPhase 272Not sealed yet
Apr 25, 2026A Study to Evaluate the Efficacy and Safety of Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA) in Patient With Breast Cancer Undergoing ChemotherapyNCT07669506 · Nuvastatic ™, PlaceboNatureceuticals Sdn BhdOncologyPhase 3180Not sealed yet
Apr 25, 2026A Clinical Trial of STP0404 in Adults With HIV-1 InfectionNCT05869643 · Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir)ST Pharm Co., Ltd.Infectious disease & vaccinesPhase 225Not sealed yet
Apr 27, 2026A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma MultiformeNCT04762069 · Berubicin, LomustineCNS Pharmaceuticals, Inc.OncologyPhase 2252Not sealed yet
Apr 27, 2026A Dose-finding Study of JMKX003142 in Treatment of Renal EdemaNCT06670534 · JMKX003142 tablets, Placebo TabletsJemincareKidneyPhase 2133Not sealed yet
Apr 28, 2026A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT07081958 · RO7795081, PlaceboHoffmann-La RocheDiabetes & obesityPhase 2352Not sealed yet
Apr 28, 2026ASKC200 for Knee Osteoarthritis PainNCT07742852 · 5% ASKC200, 1% Diclofenac Diethylamine Emulgel, PlaceboJiangsu Aosaikang Pharmaceutical Co., Ltd.Immunology & inflammationPhase 2175Not sealed yet
Apr 28, 2026ABTECT - MaintenanceNCT05535946 · ABX464, PlaceboAbivax S.A.Immunology & inflammationPhase 31,116Not sealed yet
Apr 28, 2026A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation PowderNCT07252908 · TQC3721 inhalation powder, Placebo for TQC3721 inhalation powderChia Tai Tianqing Pharmaceutical Group Co., Ltd.RespiratoryPhase 2195Not sealed yet
Apr 29, 2026Efficacy of a Stannous Fluoride Toothpaste, Cetylpyridinium Chloride Mouthwash, and Battery Toothbrush Regimen in Reducing Established Dental Plaque and Gingivitis.NCT07398846 · 0.454%Stannous fluoride toothpaste, 0.075% Cetylpyridinium Chloride (CPC) and 0.28% zinc lactatmouthwashe, 0.76% Sodium Monofluorophosphate (Na MFP) toothpasteColgate PalmoliveOtherPhase 3134Not sealed yet
Apr 29, 2026Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular DegenerationNCT06223958 · OTX-TKI (axitinib implant), AfliberceptOcular Therapeutix, Inc.OphthalmologyPhase 3344Not sealed yet
Apr 29, 2026A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery DiseaseNCT06717074 · RBD4059, PlaceboRibocure Pharmaceuticals ABCardiovascularPhase 230Not sealed yet
Apr 30, 2026A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell LymphomaNCT03274492 · Polatuzumab Vedotin, Rituximab, CyclophosphamideHoffmann-La RocheOncologyPhase 31,000Not sealed yet
Apr 30, 2026Phase IIa Study Evaluating AZD7798 in Crohn's DiseaseNCT06450197 · AZD7798, PlaceboAstraZenecaImmunology & inflammationPhase 2120Not sealed yet
Apr 30, 2026Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBSNCT03905707 · glepaglutideZealand PharmaEndocrine & bonePhase 3150Not sealed yet
Apr 30, 2026TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)NCT06082635 · TGRX-326, CrizotinibShenzhen TargetRx Co., Ltd.OncologyPhase 3321Not sealed yet
May 2026Efficacy and Safety of ELIXCYTE Intra-articular Injection in Subject With Knee OsteoarthritisNCT05526001 · ELIXCYTE, SalineUnicoCell Biomed CO. LTDImmunology & inflammationPhase 3165Not sealed yet
May 2026A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis DNCT06505928 · hepalatideShanghai HEP Pharmaceutical Co., Ltd.Infectious disease & vaccinesPhase 290Not sealed yet
May 2026Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal SyndromeNCT06256432 · Ambrisentan, TerlipressinNoorik Biopharmaceuticals AGLiverPhase 254Not sealed yet
May 2026A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsNCT06728124 · GZR18, PlaceboGan & Lee Pharmaceuticals.Diabetes & obesityPhase 3630Not sealed yet
May 2026Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)NCT05531526 · AR1001, PlaceboAriBio Co., Ltd.NeurologyPhase 31,535Not sealed yet
May 2026A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical CancerNCT05235516 · AK104, EBRT, BTAkesoOncologyPhase 3636Not sealed yet
May 1, 2026Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in ChinaNCT07135986 · MenACYW conjugate vaccine, MenACYW135 polysaccharide vaccine, MenAC conjugate vaccineSanofiInfectious disease & vaccinesPhase 31,602Not sealed yet
May 1, 2026A Study of Mevidalen (LY3154207) in Participants With Alzheimer's DiseaseNCT06538116 · Mevidalen, PlaceboEli Lilly and CompanyNeurologyPhase 2304Not sealed yet
May 1, 2026A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM PatientsNCT06254014 · Exendin-4 Fc fusion protein injection, Exendin-4 Fc fusion protein injection, PlaceboBeijing Dongfang Biotech Co., Ltd.Diabetes & obesityPhase 3270Not sealed yet
May 1, 2026A Study of NE3107 in Early Parkinson'sNCT06757010 · NE3107, PlaceboBioVie Inc.NeurologyPhase 257Not sealed yet
May 4, 2026Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderNCT06058039 · NMRA-335140, PlaceboNeumora Therapeutics, Inc.PsychiatryPhase 3422Not sealed yet
May 5, 2026Study of Sunobinop on Alcohol Consumption in Alcohol Use DisorderNCT06545916 · Sunobinop, Placebo to match sunobinopKnoa Pharma LLCPsychiatryPhase 2209Not sealed yet
May 5, 2026Multiprofen-CC™ to Reduce Pain After Total Knee ArthroplastyNCT06202989 · Multiprofen-CC™ plus standard treatment, Placebo plus standard treatmentKAZM Pharmaceuticals Inc.PainPhase 3306Not sealed yet
May 6, 2026Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.NCT07212426 · LP-005 InjectionLongbio PharmaHematologyPhase 230Not sealed yet
May 6, 2026Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06058013 · NMRA-335140, PlaceboNeumora Therapeutics, Inc.PsychiatryPhase 3430Not sealed yet
May 6, 2026Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)NCT06060665 · Seladelpar 10 mg, PlaceboGilead SciencesLiverPhase 396Not sealed yet
May 6, 2026A Study of Barzolvolimab in Patients With Atopic DermatitisNCT06727552 · Barzolvolimab, Matching placeboCelldex TherapeuticsImmunology & inflammationPhase 2131Not sealed yet
May 6, 2026Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)NCT06593600 · REGN7544, PlaceboRegeneron PharmaceuticalsCardiovascularPhase 282Not sealed yet
May 7, 2026Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 MutationNCT06780930 · Vorasidenib, PlaceboServierOncologyPhase 357Not sealed yet
May 7, 2026A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.NCT06899217 · CIN-102 Dose 15mg, Placebo, CIN-102 Dose 10mgCinDome Pharma, Inc.Endocrine & bonePhase 2416Not sealed yet
May 8, 2026Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot UlcersNCT06531512 · Xianglei Tangzu Gao, Vehicle CreamOneness Biotech Co., Ltd.Diabetes & obesityPhase 2/3120Not sealed yet
May 8, 2026Evaluate the Efficacy and Safety of FB704A in Adult With Severe AsthmaNCT05018299 · FB704A placebo, FB704AOneness Biotech Co., Ltd.RespiratoryPhase 221Not sealed yet
May 8, 2026A Phase 2 Study of JNT-517 in Adolescent Participants With PhenylketonuriaNCT06637514 · JNT-517 Tablet, Placebo, JNT-517 TabletOtsuka Pharmaceutical Development & Commercialization, Inc.Rare genetic diseasePhase 214Not sealed yet
May 11, 2026A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesNCT05976243 · Remibrutinib, PlaceboNovartis PharmaceuticalsImmunology & inflammationPhase 3362Not sealed yet
May 11, 2026A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and OlderNCT07121192 · Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1GlaxoSmithKlineInfectious disease & vaccinesPhase 2776Not sealed yet
May 11, 2026Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular AtrophyNCT05794139 · NMD670, PlaceboNMD Pharma A/SRare genetic diseasePhase 252Not sealed yet
May 11, 2026A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs AloneNCT06862791 · AZD9550, AZD6234, Placebo comparatorAstraZenecaDiabetes & obesityPhase 2377Not sealed yet
May 11, 2026A Study of ONO-1110 in Patients With Postherpetic NeuralgiaNCT06708416 · ONO-1110, PlaceboOno Pharmaceutical Co., Ltd.PainPhase 2142Not sealed yet
May 12, 2026Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on DialysisNCT07119372 · BCD-131 (pegdarbepoetin beta), Mircera (methoxypolyethylene glycol-epoetin beta)BiocadKidneyPhase 3228Not sealed yet
May 12, 2026A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)NCT06924970 · Tebapivat, Tebapivat Matched PlaceboAgios Pharmaceuticals, Inc.HematologyPhase 259Not sealed yet
May 13, 2026A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))NCT05731128 · Dupilumab, PlaceboSanofiImmunology & inflammationPhase 268Not sealed yet
May 13, 2026Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)NCT05248646 · Sibeprenlimab 400 mg, PlaceboOtsuka Pharmaceutical Development & Commercialization, Inc.KidneyPhase 3530Not sealed yet
May 13, 2026A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot DermatitisNCT06921759 · Lebrikizumab, PlaceboEli Lilly and CompanyImmunology & inflammationPhase 3221Not sealed yet
May 13, 2026A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MINCT04825743 · zalunfiban, PlaceboCeleCor TherapeuticsCardiovascularPhase 32,463Not sealed yet
May 13, 2026EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid CardiomyopathyNCT06194825 · Eplontersen, PlaceboAstraZenecaOphthalmologyPhase 364Not sealed yet
May 14, 2026A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerNCT07553988 · RS-113, 160 mg, RS-113, 240 mg, RS-113, 320 mgR-Pharm International, LLCOncologyPhase 2120Not sealed yet
May 14, 2026GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's DiseaseNCT05686551 · Tominersen, PlaceboHoffmann-La RocheNeurologyPhase 2301Not sealed yet
May 14, 2026Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)NCT06999902 · 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, PlaceboPraxis Precision MedicinesNeurologyPhase 2/3255Not sealed yet
May 15, 2026Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentNCT03847428 · Durvalumab, Bevacizumab, PlaceboAstraZenecaOncologyPhase 3908Not sealed yet
May 15, 2026A Study of AK112 With or Without AK117 in Metastatic Colorectal CancerNCT05382442 · AK112, AK117, OxaliplatinAkesoOncologyPhase 2254Not sealed yet
May 15, 2026Efficacy & Safety of Minoxidil SL Tablets in Men With AGANCT06924632 · Minoxidil, PlaceboSamson Clinical Operations Pty LtdImmunology & inflammationPhase 3142Not sealed yet
May 15, 2026Study of Lumateperone in the Treatment of Patients With Bipolar ManiaNCT06462612 · Lumateperone, PlaceboIntra-Cellular Therapies, Inc.PsychiatryPhase 3351Not sealed yet
May 15, 2026Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in AdultsNCT07404579 · HRS-9190, HRS-9190, HRS-9190Jiangsu HengRui Medicine Co., Ltd.OtherPhase 2103Not sealed yet
May 18, 2026Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection FractionNCT06017609 · JTT-861 Capsules, Placebo CapsulesAkros Pharma Inc.CardiovascularPhase 2314Not sealed yet
May 18, 2026Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07168902 · BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%Bausch & Lomb IncorporatedOphthalmologyPhase 2252Not sealed yet
May 18, 2026A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerNCT06012435 · sigvotatug vedotin, docetaxelSeagen, a wholly owned subsidiary of PfizerOncologyPhase 3762Not sealed yet
May 19, 2026A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerNCT06497556 · Divarasib, Sotorasib, AdagrasibHoffmann-La RocheOncologyPhase 3338Not sealed yet
May 20, 2026Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver FibrosisNCT05327127 · K-877-ER, CSG452, PlaceboKowa Research Institute, Inc.LiverPhase 2228Not sealed yet
May 20, 2026Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).NCT07264517 · GRF312 5%, Placebo ComparatorInstituto Grifols, S.A.OphthalmologyPhase 2103Not sealed yet
May 20, 2026A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · Placebo, DT120Definium Therapeutics US, Inc.PsychiatryPhase 3149Not sealed yet
May 22, 2026A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseaseNCT05280548 · Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828)SanofiRare genetic diseasePhase 3104Not sealed yet
May 22, 2026A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic MyopiaNCT06176352 · Faricimab, Ranibizumab, Sham ProcedureHoffmann-La RocheOphthalmologyPhase 3280Not sealed yet
May 23, 2026Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCLNCT06601504 · HMPL-760 planned dose 1, R-GemOx, HMPL-760 placebo planned dose 1HutchmedOncologyPhase 261Not sealed yet
May 25, 2026A Study of ONO-1110 in Patients With Social Anxiety DisorderNCT06805565 · ONO-1110, PlaceboOno Pharmaceutical Co., Ltd.PsychiatryPhase 2115Not sealed yet
May 25, 2026A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersNCT06143046 · mRNA-1345, PlaceboModernaTX, Inc.Infectious disease & vaccinesPhase 2360Not sealed yet
May 25, 2026A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic ArthritisNCT06878404 · Icotrokinra, Placebo, Active reference comparatorJanssen Research & Development, LLCImmunology & inflammationPhase 3552Not sealed yet
May 26, 2026Study to Assess the Efficacy of EMC-CAP-2025A on Age-Related Skin Parameters in Healthy IndividualsNCT07493850 · EMC-CAP-2025A, EMC-CAP-2025BCircul'EggOtherPhase 260Not sealed yet
May 26, 2026A Study of Mosliciguat in PH-ILDNCT06635850 · Mosliciguat, Dry Powder Inhaler, PlaceboPulmovant, Inc.CardiovascularPhase 2135Not sealed yet
May 26, 2026A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)NCT06490445 · Medical Cannabis, PlaceboSyqe MedicalDiabetes & obesityPhase 2122Not sealed yet
May 26, 2026Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AgonistNCT06851858 · AZD6234, Placebo to matchAstraZenecaDiabetes & obesityPhase 269Not sealed yet
May 26, 2026Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma SubjectsNCT07054034 · MG-ZG122 Humanized Monoclonal Antibody Injection, PlaceboShanghai Mabgeek Biotech.Co.LtdRespiratoryPhase 2160Not sealed yet
May 26, 2026A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of AgeNCT06087640 · aQIV or aTIV, QIV or TIVSeqirusInfectious disease & vaccinesPhase 338,769Not sealed yet
May 27, 2026Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes MellitusNCT07055516 · NT-0796, PlaceboRezera (formerly NodThera Limited)Diabetes & obesityPhase 2176Not sealed yet
May 27, 2026A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)NCT05996471 · VH3810109, Cabotegravir, Standard of care (SOC)ViiV HealthcareInfectious disease & vaccinesPhase 2185Not sealed yet
May 27, 2026A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)NCT07716618 · SAL0120 1mg, SAL0120 2mg, SAL0120 4mgShenzhen Salubris Pharmaceuticals Co., Ltd.KidneyPhase 2320Not sealed yet
May 27, 2026A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationNCT03383458 · Nivolumab, PlaceboBristol-Myers SquibbOncologyPhase 3545Not sealed yet
May 27, 2026A Trial of Remimazolam for Intraoperative Sedation in Pediatric and Adolescent PatientsNCT07036419 · Remimazolam Tosilate for injection, Propofol InjectionJiangsu HengRui Medicine Co., Ltd.OtherPhase 2/3249Not sealed yet
May 27, 2026Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERDNCT05556824 · MHS-1031, PlaceboMicrobiome Health SciencesOtherPhase 2255Not sealed yet
May 27, 2026Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With KeratoconusNCT06100939 · Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatmentEpion TherapeuticsOphthalmologyPhase 3396Not sealed yet
May 28, 2026A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseNCT07128628 · Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, PerfluorohexyloctaneBausch & Lomb IncorporatedOphthalmologyPhase 2443Not sealed yet
May 28, 2026A Study to Learn More About How Well Oxymetazoline HCl 0.05% Nasal Gel Works and How Safe It Is in Healthy AdultsNCT07582328 · Oxymetazoline HCl 0.05% nasal gel, Placebo nasal gelBayerOtherPhase 2120Not sealed yet
May 28, 2026A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)NCT07155668 · VRDN-003, AutoinjectorViridian Therapeutics, Inc.OphthalmologyPhase 387Not sealed yet
May 28, 2026A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in AdultsNCT06047444 · Botulinum toxin type A, Botulinum toxin type A, PlaceboIpsenNeurologyPhase 3759Not sealed yet
May 28, 2026Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)NCT06513312 · Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF)Gilead SciencesInfectious disease & vaccinesPhase 2268Not sealed yet
May 29, 2026A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With MetforminNCT06589765 · HRS-7535 tablet, dapagliflozin tabletShandong Suncadia Medicine Co., Ltd.Diabetes & obesityPhase 3810Not sealed yet
May 29, 2026Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μgNCT05569239 · OVX836 480µg, Saline SolutionOsivaxInfectious disease & vaccinesPhase 22,850Not sealed yet
May 29, 2026Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)NCT06873516 · EVO756, EVO756, EVO756Evommune, Inc.Immunology & inflammationPhase 2182Not sealed yet
May 29, 2026A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362 · Placebo, EnicepatideCarmot Therapeutics, Inc.Diabetes & obesityPhase 2447Not sealed yet
May 30, 2026A Clinical Study of ONO-1110 in Patients With FibromyalgiaNCT06752590 · ONO-1110, PlaceboOno Pharmaceutical Co., Ltd.OtherPhase 2175Not sealed yet
May 31, 2026AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2NCT06346392 · AZD0901, AZD0901, Ramucirumab+ paclitaxelAstraZenecaOncologyPhase 3594Not sealed yet
May 31, 2026A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersNCT06044350 · BAT4406F Injection, BAT4406F PlacebosBio-Thera SolutionsOtherPhase 2162Not sealed yet
May 31, 2026Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video ObservationNCT06691256 · HiDO-ALZHiDO TechnologiesDiabetes & obesityPhase 270Not sealed yet
Jun 20269-ING-41 in Patients With Advanced CancersNCT03678883 · 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin.Actuate Therapeutics Inc.OncologyPhase 2350Not sealed yet
Jun 2026Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque PsoriasisNCT06640517 · Netakimab, Placebo, AdalimumabBiocadImmunology & inflammationPhase 3140Not sealed yet
Jun 2026A Study of Telitacicept for IgA Nephropathy (TELIGAN)NCT05799287 · Telitacicept, PlaceboRemeGen Co., Ltd.KidneyPhase 3318Not sealed yet
Jun 2026A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisNCT05526222 · Jaktinib Hydrochloride TabletSuzhou Zelgen Biopharmaceuticals Co.,LtdImmunology & inflammationPhase 3443Not sealed yet
Jun 2026A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or RecurrenceNCT06336291 · L19TNF, L19TNF, L19TNFPhilogen S.p.A.OncologyPhase 290Not sealed yet
Jun 2026A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.NCT06720896 · APT-001 topical ophthalmic ointment (spinosad), Vehicle control for APT-001 topical ophthalmic ointmentAperta Biosciences, LLCOtherPhase 2100Not sealed yet
Jun 2026Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)NCT06625320 · RMC-6236, Gemcitabine, nab-paclitaxelRevolution Medicines, Inc.OncologyPhase 3500Not sealed yet
Jun 2026Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette SyndromeNCT06315751 · Gemlapodect, PlaceboNoema Pharma AGOtherPhase 2164Not sealed yet
Jun 1, 2026Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerNCT03682068 · Durvalumab, Tremelimumab, Cisplatin + GemcitabineAstraZenecaOncologyPhase 31,246Not sealed yet
Jun 1, 2026A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · survodutide, PlaceboBoehringer IngelheimDiabetes & obesityPhase 35,531Not sealed yet
Jun 1, 2026Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaNCT06347133 · Plozasiran Injection, PlaceboArrowhead PharmaceuticalsDiabetes & obesityPhase 31,456Not sealed yet
Jun 1, 2026A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in AdultsNCT06047457 · Botulinum toxin type A, Botulinum toxin type A, PlaceboIpsenNeurologyPhase 3751Not sealed yet
Jun 1, 2026Clinical Study to Assess the Efficacy of New Toothpaste Containing SnF as Compared to Colgate Cavity Protection Toothpaste on the Reduction of Enamel ErosionNCT07442136 · New Toothpaste Containing SnF, Fluoride ToothpasteColgate PalmoliveOtherPhase 380Not sealed yet
Jun 2, 2026A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT06075667 · Tirzepatide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3160Not sealed yet
Jun 2, 2026A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 · Cagrilintide, Semaglutide, TirzepatideNovo Nordisk A/SDiabetes & obesityPhase 31,023Not sealed yet
Jun 3, 2026A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaNCT04712097 · Mosunetuzumab, Lenalidomide, RituximabHoffmann-La RocheOncologyPhase 3478Not sealed yet
Jun 4, 2026A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaNCT07038876 · Placebo, ML-007C-MA BID, ML-007C-MA QDMapLight TherapeuticsPsychiatryPhase 2307Not sealed yet
Jun 5, 2026A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United StatesNCT07122193 · NT 201, NT 201 PlaceboMerz North America, Inc.OtherPhase 3300Not sealed yet
Jun 5, 2026A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic ArthritisNCT06640257 · SHR-1314 injection, PlaceboSuzhou Suncadia Biopharmaceuticals Co., Ltd.Immunology & inflammationPhase 3208Not sealed yet
Jun 6, 2026Bacterial Reduction for a Manual Toothbrush With a 360-Degree Mouth Cleaner Design Versus a Standard ToothbrushNCT07471477 · Colgate 360 SupraClean Manual Toothbrush brush with 0.76% Na MFP, (1000 ppm F), Colgate Adult Extra Clean soft-bristle toothbrush brush with 0.76% Na MFP, (1000 ppm F)Colgate PalmoliveOtherPhase 356Not sealed yet
Jun 7, 2026A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody TherapyNCT06945107 · Picankibart, Secukinumab, PlaceboInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Immunology & inflammationPhase 3308Not sealed yet
Jun 7, 2026A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis BNCT07135349 · BW-20507 with/without NUC, BW-20507 with/without NUC, Peg-IFNaShanghai Argo Biopharmaceutical Co., Ltd.Infectious disease & vaccinesPhase 2209Not sealed yet
Jun 8, 2026A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)NCT06687980 · Dupilumab, PlaceboSanofiOtherPhase 3138Not sealed yet
Jun 8, 2026A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)NCT06687967 · Dupilumab, PlaceboSanofiOtherPhase 3142Not sealed yet
Jun 9, 2026ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and InflammationNCT05021835 · Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B)Novo Nordisk A/SCardiovascularPhase 36,385Not sealed yet
Jun 9, 2026Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)NCT06151197 · EN3835, PlaceboEndo USA Inc., a Keenova Therapeutics CompanyOtherPhase 3436Not sealed yet
Jun 9, 2026A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsNCT05048797 · Trastuzumab Deruxtecan, Cisplatin, CarboplatinAstraZenecaOncologyPhase 3454Not sealed yet
Jun 10, 2026A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisNCT06407934 · Amlitelimab, PlaceboSanofiImmunology & inflammationPhase 31,541Not sealed yet
Jun 10, 2026An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)NCT06073132 · AC-203, VehicleTWi Biotechnology, Inc.OtherPhase 2/380Not sealed yet
Jun 10, 2026A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkNCT06290128 · Riliprubart, Placebo, RiliprubartSanofiNeurologyPhase 3109Not sealed yet
Jun 10, 2026DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)NCT06539195 · DZD8586, DZD8586, DZD8586Dizal PharmaceuticalsOncologyPhase 259Not sealed yet
Jun 10, 2026A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughNCT05600777 · BLU-5937, PlaceboBellus Health Inc. - a GSK companyOtherPhase 3997Not sealed yet
Jun 12, 2026A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial CystitisNCT06752603 · ONO-1110, PlaceboOno Pharmaceutical Co., Ltd.OtherPhase 257Not sealed yet
Jun 12, 2026Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaNCT06347003 · Plozasiran Injection, PlaceboArrowhead PharmaceuticalsDiabetes & obesityPhase 3446Not sealed yet
Jun 12, 2026A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)NCT04895696 · Afimetoran, PlaceboBeeline Medicines CorporationImmunology & inflammationPhase 2248Not sealed yet
Jun 12, 2026A Study of TLC590 for Postsurgical Pain Following BunionectomyNCT07222748 · TLC590, Liposomal Bupivacaine, Saline PlaceboTLC Biopharmaceuticals, Inc.PainPhase 3304Not sealed yet
Jun 14, 2026A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep DisturbancesNCT06685965 · RE03, PlaceboReconnect LabsPsychiatryPhase 212Not sealed yet
Jun 15, 2026A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in AdultsNCT06742281 · CVXGA (CVXGA50), COMIRNATY®CyanVac LLCInfectious disease & vaccinesPhase 2432Not sealed yet
Jun 15, 2026A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic StrokeNCT05953480 · Redasemtide, PlaceboShionogiCardiovascularPhase 2680Not sealed yet
Jun 15, 2026Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)NCT05298423 · pembrolizumab/vibostolimab, durvalumab, cisplatinMerck Sharp & Dohme LLCOncologyPhase 3610Not sealed yet
Jun 15, 2026Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughNCT06504446 · NOC-110, PlaceboNocion TherapeuticsOtherPhase 2455Not sealed yet
Jun 16, 2026A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.NCT06383403 · Elafibranor, PlaceboIpsenLiverPhase 392Not sealed yet
Jun 16, 2026A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationNCT06299098 · Trevogrumab-Part A, Trevogrumab-Part B and Part C, GaretosmabRegeneron PharmaceuticalsDiabetes & obesityPhase 21,005Not sealed yet
Jun 16, 2026A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05692492 · ZSP1601, ZSP1601, PlaceboGuangdong Raynovent Biotech Co., LtdLiverPhase 2180Not sealed yet
Jun 16, 2026A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · Retatrutide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 31,152Not sealed yet
Jun 16, 2026Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerNCT05425940 · XL092, Atezolizumab, RegorafenibExelixisOncologyPhase 3901Not sealed yet
Jun 17, 2026A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) LesionsNCT07275814 · HRS-9231 Injection, Gadobutrol Injection, Magnetic Resonance Imaging (MRI)Shanghai Shengdi Pharmaceutical Co., LtdOtherPhase 3250Not sealed yet
Jun 17, 2026Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)NCT07811882 · KAE609 (Cipargamin), SoC (Coartem), INE963Novartis PharmaceuticalsInfectious disease & vaccinesPhase 295Not sealed yet
Jun 17, 2026FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)NCT04768972 · ION363, PlaceboIonis Pharmaceuticals, Inc.OncologyPhase 389Not sealed yet
Jun 17, 2026Study of Plozasiran in Adults With Severe HypertriglyceridemiaNCT06347016 · Plozasiran Injection, PlaceboArrowhead PharmaceuticalsDiabetes & obesityPhase 3311Not sealed yet
Jun 17, 2026Vaginal Photobiomodulation for Chronic Pelvic PainNCT06673108 · SoLa Pelvic Therapy, ShamSoLa Pelvic TherapyPainPhase 2128Not sealed yet
Jun 18, 2026Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD SubjectsNCT07024212 · DR10624 Injection, PlaceboZhejiang Doer Biologics Co., Ltd.LiverPhase 2110Not sealed yet
Jun 18, 2026A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）NCT04587908 · TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort], Placebo [Ambulatory Cohort] onlyTaiho Pharmaceutical Co., Ltd.Rare genetic diseasePhase 3104Not sealed yet
Jun 18, 2026RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)NCT04567550 · ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3AbbVieOphthalmologyPhase 2139Not sealed yet
Jun 19, 2026A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerNCT05217446 · Encorafenib, Cetuximab, PembrolizumabPfizerOncologyPhase 2108Not sealed yet
Jun 19, 2026A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular LymphomaNCT06425302 · Golcadomide, Rituximab, CyclophosphamideCelgeneOncologyPhase 295Not sealed yet
Jun 20, 2026STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's DiseaseNCT05843578 · AGMB-129, PlaceboAgomab Spain S.L.U.Immunology & inflammationPhase 2103Not sealed yet
Jun 22, 2026Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy VolunteersNCT07560150 · I004, NovoLogAmphastar Pharmaceuticals, Inc.OtherPhase 2/362Not sealed yet
Jun 22, 2026Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)NCT04336722 · Odevixibat, PlaceboAlbireo, an Ipsen CompanyLiverPhase 3254Not sealed yet
Jun 23, 2026A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)NCT06643481 · VHB937, PlaceboNovartis PharmaceuticalsNeurologyPhase 2251Not sealed yet
Jun 23, 2026Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusNCT05966480 · Envudeucitinib, PlaceboAlumis IncImmunology & inflammationPhase 2408Not sealed yet
Jun 24, 2026A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate CancerNCT06395753 · Debio 4228Debiopharm International SAOncologyPhase 255Not sealed yet
Jun 25, 2026Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to TrikaftaNCT07108153 · SION-719, Placebo-to-match SION-719Sionna Therapeutics Inc.RespiratoryPhase 215Not sealed yet
Jun 25, 2026A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone TherapyNCT06440967 · Fezolinetant, Placebo, TamoxifenAstellas Pharma Global Development, Inc.OncologyPhase 3982Not sealed yet
Jun 25, 2026A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive DisorderNCT06785012 · JNJ-89495120, PlaceboJanssen Research & Development, LLCPsychiatryPhase 2105Not sealed yet
Jun 25, 2026Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive DisorderNCT07018245 · TJ0113, PlaceboHangzhou PhecdaMed Co., Ltd.PsychiatryPhase 2149Not sealed yet
Jun 26, 2026A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 · CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Novo Nordisk A/SDiabetes & obesityPhase 2142Not sealed yet
Jun 26, 2026Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in SubjectsNCT04505436 · HM15211, Placebo of HM15211Hanmi Pharmaceutical Company LimitedLiverPhase 2215Not sealed yet
Jun 26, 2026Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to OsteoarthritisNCT06257537 · Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac PatchesZetrOZ, Inc.Immunology & inflammationPhase 2307Not sealed yet
Jun 26, 2026A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseNCT04711252 · AZD9833, Anastrozole, Anastrozole placeboAstraZenecaOncologyPhase 31,371Not sealed yet
Jun 28, 2026A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes MellitusNCT07055386 · GZR102, GZR18Gan & Lee Pharmaceuticals.Diabetes & obesityPhase 290Not sealed yet
Jun 28, 2026Study to Investigate Toothpaste on Antibacterial Effects in the Different Regions of the MouthNCT07458464 · stannous fluoride toothpaste, 0.76% Sodium Monofluorophosphate (Na MFP) toothpasteColgate PalmoliveOtherPhase 395Not sealed yet
Jun 29, 2026A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy AdultsNCT07047521 · Tetravalent Dengue Vaccine (TDV)TakedaInfectious disease & vaccinesPhase 3496Not sealed yet
Jun 29, 2026A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 DiabetesNCT07271251 · Oral semaglutideNovo Nordisk A/SDiabetes & obesityPhase 3267Not sealed yet
Jun 29, 2026A Phase 2b Study of Zagociguat in Patients With MELASNCT06402123 · zagociguat 15mg, zagociguat 30mg, PlaceboTisento TherapeuticsCardiovascularPhase 243Not sealed yet
Jun 29, 2026Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineNCT06806293 · Atogepant, Placebo for AtogepantAbbVieNeurologyPhase 3468Not sealed yet
Jun 30, 2026A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)NCT06472076 · Dostarlimab, Belrestotug, PembrolizumabGlaxoSmithKlineOncologyPhase 388Not sealed yet
Jun 30, 2026A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)NCT05816252 · SKB264, Pembrolizumab, CarboplatinKlus Pharma Inc.OncologyPhase 2356Not sealed yet
Jun 30, 2026A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal CancerNCT05652894 · HX008(Pucotenlimab), Investigator's Choice ChemotherapyTaizhou Hanzhong biomedical co. LTDOncologyPhase 3190Not sealed yet
Jun 30, 2026A Phase 2 in Adult Subjects With Hereditary AngioedemaNCT06846398 · BW-20805, BW-20805, BW-20805Shanghai Argo Biopharmaceutical Co., Ltd.OtherPhase 225Not sealed yet
Jun 30, 2026Comparison of Standard vs. Accelerated Corneal CrosslinkingNCT03922542 · riboflavin 0.1%, Riboflavin 0.1%Price Vision GroupOphthalmologyPhase 2/3508Not sealed yet
Jun 30, 2026Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After ChemotherapyNCT06711523 · PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.), PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)Kexing Biopharm Co., Ltd.OncologyPhase 3250Not sealed yet
Jun 30, 2026A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRPNCT04850118 · rAAV2tYF-GRK1-hRPGRco, ControlBeacon TherapeuticsOphthalmologyPhase 2/385Not sealed yet
Jun 30, 2026Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 · Gedatolisib, Palbociclib, FulvestrantCelcuity IncOncologyPhase 3701Not sealed yet
Jun 30, 2026Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and OlderNCT05304351 · Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, ShingrixCurevo IncInfectious disease & vaccinesPhase 21,516Not sealed yet
Jun 30, 2026A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)NCT05786573 · Obexelimab, Obexelimab, PlaceboZenas BioPharma (USA), LLCHematologyPhase 3134Not sealed yet
Jun 30, 2026A Study in Patients With Mixed DyslipidemiaNCT06497127 · BW-00112Shanghai Argo Biopharmaceutical Co., Ltd.CardiovascularPhase 2145Not sealed yet
Jun 30, 2026LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFNCT05983250 · TNX-103, PlaceboTenax Therapeutics, Inc.CardiovascularPhase 3230Not sealed yet
Jun 30, 2026Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.NCT04925024 · Lomecel-B medicinal signaling cellsLongeveron Inc.CardiovascularPhase 240Not sealed yet
Jun 30, 2026A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell LymphomaNCT06485219 · 11.2 mg/m2 Purinostat Mesylate, 15 mg/m2 Purinostat MesylateChengdu Zenitar Biomedical Technology Co., LtdOncologyPhase 250Not sealed yet
Jun 30, 2026A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerNCT05353257 · HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapyShanghai Henlius BiotechOncologyPhase 3511Not sealed yet
Jul 2026A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaNCT05943795 · SI-B001, DocetaxelSichuan Baili Pharmaceutical Co., Ltd.OncologyPhase 3589Not sealed yet
Jul 2026A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH PatientsNCT06322628 · VSA006, PlaceboVisirna Therapeutics HK LimitedLiverPhase 248Not sealed yet
Jul 2026Effect of Testofen on Erectile Function in an Adult Male PopulationNCT05232279 · Testofen 300mg, Testofen 600mg, Placebo comparatorRDC Clinical Pty LtdOtherPhase 3120Not sealed yet
Jul 2026Phase 2b Study of EVO756 in Adults With Atopic DermatitisNCT07150845 · EVO756, EVO756, EVO756Evommune, Inc.Immunology & inflammationPhase 2120Not sealed yet
Jul 2026Clinical Investigation of Oral Malodor for Max Fresh Toothpaste Containing Zinc Citrate Versus a Commercially Available Regular Fluoride ToothpasteNCT07398378 · Max Fresh Toothpaste, Colgate Cavity Protection ToothpasteColgate PalmoliveOtherPhase 380Not sealed yet
Jul 2026A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCNCT04736823 · AK112, Pemetrexed, PaclitaxelAkesoOncologyPhase 2265Not sealed yet
Jul 2026Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced MelanomaNCT04674683 · HBI-8000 in combination with nivolumab, Placebo in combination with nivolumabHUYABIO International, LLC.OncologyPhase 3450Not sealed yet
Jul 1, 2026A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571 · LY3841136, Tirzepatide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 2367Not sealed yet
Jul 2, 2026A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionNCT07790120 · SAL0120, PlaceboShenzhen Salubris Pharmaceuticals Co., Ltd.CardiovascularPhase 3256Not sealed yet
Jul 2, 2026A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)NCT06465303 · RTP-026, PlaceboResoTher PharmaCardiovascularPhase 266Not sealed yet
Jul 2, 2026A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.NCT05523167 · EFG PH20 SC, PBOargenxOtherPhase 2/3265Not sealed yet
Jul 6, 2026A Study to Evaluate Solriktug in Adult Participants With AsthmaNCT06496607 · NSI-8226, NSI-8226, NSI-8226Uniquity One (UNI)RespiratoryPhase 2145Not sealed yet
Jul 6, 2026Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentNCT05261399 · Savolitinib, Osimertinib, PemetrexedAstraZenecaOncologyPhase 3341Not sealed yet
Jul 6, 2026A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804 · Tirzepatide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 2134Not sealed yet
Jul 7, 20264-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsNCT06553547 · Tenapanor, PlaceboArdelyxOtherPhase 272Not sealed yet
Jul 7, 2026A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyNCT04666610 · Brivaracetam, PlaceboUCB Biopharma SRLNeurologyPhase 3153Not sealed yet
Jul 8, 2026A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive DisorderNCT06254612 · SP-624, PlaceboSirtsei Pharmaceuticals, Inc.PsychiatryPhase 2497Not sealed yet
Jul 8, 2026Avexitide for Treatment of Post-Bariatric HypoglycemiaNCT06747468 · Avexitide, PlaceboAmylyx Pharmaceuticals Inc.Diabetes & obesityPhase 375Not sealed yet
Jul 9, 2026Phase 2 Study of MWN109 Tablet in Participants With Overweight or ObesityNCT07791524 · MWN109 1, MWN109 2, MWN109 3Shanghai Minwei Biotechnology Co., LtdDiabetes & obesityPhase 2255Not sealed yet
Jul 9, 2026A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaNCT04039607 · Nivolumab, Ipilimumab, SorafenibBristol-Myers SquibbOncologyPhase 3732Not sealed yet
Jul 10, 2026A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesNCT06564844 · Datopotamab Deruxtecan, Rilvegostomig, CarboplatinAstraZenecaOncologyPhase 325Not sealed yet
Jul 10, 2026Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)NCT06617429 · GTX-102, Sham-LPUltragenyx Pharmaceutical IncOtherPhase 3129Not sealed yet
Jul 13, 2026A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56NCT06668064 · EYP-1901, Aflibercept (2.0 mg)EyePoint Pharmaceuticals, Inc.OphthalmologyPhase 3400Not sealed yet
Jul 14, 2026A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaNCT06748053 · GSK5784283, PlaceboGlaxoSmithKlineRespiratoryPhase 2307Not sealed yet
Jul 14, 2026ELAPR002f Injectable Gel in the Treatment of Atrophic Acne ScarsNCT05995340 · ELAPR002f Injectable Gel, Saline Active ControlAbbVieOtherPhase 3157Not sealed yet
Jul 14, 2026Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisNCT05583227 · Tezepelumab, Tezepelumab, PlaceboAstraZenecaOtherPhase 3368Not sealed yet
Jul 14, 2026A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisNCT06254950 · TAK-279, PlaceboTakedaImmunology & inflammationPhase 2213Not sealed yet
Jul 14, 2026Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in AdultsNCT07446309 · HRS-9190; under Inhalational Anesthesia, HRS-9190; under Intravenous Anesthesia, Cisatracurium (under Inhalational Anesthesia).Jiangsu HengRui Medicine Co., Ltd.OtherPhase 267Not sealed yet
Jul 15, 2026A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)NCT06741228 · Placebo, DT120Definium Therapeutics US, Inc.PsychiatryPhase 3214Not sealed yet
Jul 15, 2026Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV)NCT07774364 · AT-004, PlaceboArctic TherapeuticsOtherPhase 263Not sealed yet
Jul 15, 2026Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT05814627 · Upadacitinib, Adalimumab, Upadacitinib Matching PlaceboAbbVieImmunology & inflammationPhase 3487Not sealed yet
Jul 15, 2026A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersNCT05152147 · Zanidatamab, Tislelizumab, TrastuzumabJazz PharmaceuticalsOncologyPhase 3920Not sealed yet
Jul 15, 2026Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle WeaknessNCT06600581 · IMM01-STEM, Placebo, IMM01-STEM alternating with placebo (saline)Immunis, Inc.Diabetes & obesityPhase 255Not sealed yet
Jul 15, 2026A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerNCT06057610 · SHR-A1811 Injection, SHR-A1811 Injection ； Pertuzumab Injection, Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu HengRui Medicine Co., Ltd.OncologyPhase 3868Not sealed yet
Jul 16, 2026Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDNCT04023552 · TQJ230, PlaceboNovartis PharmaceuticalsCardiovascularPhase 38,323Not sealed yet
Jul 17, 2026Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)NCT06940141 · Rademikibart in prefilled syringe, Matching placebo in prefilled syringeConnect Biopharm LLCRespiratoryPhase 2160Not sealed yet
Jul 18, 2026A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesNCT06649344 · HRS9531 Injection, Semaglutide InjectionFujian Shengdi Pharmaceutical Co., Ltd.Diabetes & obesityPhase 3884Not sealed yet
Jul 20, 2026A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus DiseaseNCT07220109 · RSVPreF3 OA vaccine, PlaceboGlaxoSmithKlineInfectious disease & vaccinesPhase 3750Not sealed yet
Jul 21, 2026Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)NCT05147220 · Remibrutinib, TeriflunomideNovartis PharmaceuticalsNeurologyPhase 31,000Not sealed yet
Jul 21, 2026A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · Orforglipron, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3712Not sealed yet
Jul 21, 2026A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years OldNCT02616302 · DexlansoprazoleTakedaOtherPhase 271Not sealed yet
Jul 21, 2026Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLNCT05164341 · metreleptin, PlaceboChiesi Farmaceutici S.p.A.OtherPhase 369Not sealed yet
Jul 22, 2026Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)NCT05156281 · Remibrutinib, TeriflunomideNovartis PharmaceuticalsNeurologyPhase 31,007Not sealed yet
Jul 22, 2026Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCINCT05758896 · Isuzinaxib (APX-115), PlaceboAptabio Therapeutics, Inc.KidneyPhase 2218Not sealed yet
Jul 22, 2026Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)NCT06101329 · Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)Gilead SciencesInfectious disease & vaccinesPhase 2253Not sealed yet
Jul 22, 2026Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionNCT07354516 · QLS-111-FDC, Latanoprost (0.005%)Qlaris Bio, Inc.OphthalmologyPhase 2/364Not sealed yet
Jul 22, 2026A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic DermatitisNCT06863961 · Afimkibart, PlaceboHoffmann-La RocheImmunology & inflammationPhase 2162Not sealed yet
Jul 22, 2026A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyNCT04543617 · Tiragolumab, Atezolizumab, Tiragolumab Matching PlaceboHoffmann-La RocheOncologyPhase 3760Not sealed yet
Jul 23, 2026A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease ActivityNCT06104124 · Dazodalibep, PlaceboAmgenImmunology & inflammationPhase 3651Not sealed yet
Jul 23, 2026A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07281937 · VRB-101, PlaceboVerdiva Bio Dev LimitedDiabetes & obesityPhase 2206Not sealed yet
Jul 23, 2026Global Study of Del-desiran for the Treatment of DM1NCT06411288 · AOC 1001 (del-desiran), PlaceboAvidity Biosciences, Inc.OtherPhase 3159Not sealed yet
Jul 24, 2026A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsNCT06067230 · mRNA-1345ModernaTX, Inc.Infectious disease & vaccinesPhase 31,153Not sealed yet
Jul 27, 2026Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)NCT06101342 · Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF)Gilead SciencesInfectious disease & vaccinesPhase 2181Not sealed yet
Jul 27, 2026D9319C00001- 1L OC Mono Global RCTNCT04884360 · Olaparib, Matching placeboAstraZenecaOncologyPhase 3366Not sealed yet
Jul 27, 2026A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryNCT05608291 · Fianlimab, Cemiplimab, PembrolizumabRegeneron PharmaceuticalsOncologyPhase 31,564Not sealed yet
Jul 27, 2026A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDDNCT06236880 · GM-2505Gilgamesh PharmaceuticalsPsychiatryPhase 2126Not sealed yet
Jul 30, 2026RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513 · Pemvidutide, PlaceboAltimmune, Inc.Diabetes & obesityPhase 2100Not sealed yet
Jul 30, 2026A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.NCT06637631 · SAR441566, SAR441566 matching PlaceboSanofiImmunology & inflammationPhase 2260Not sealed yet
Jul 30, 2026A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative ColitisNCT07035041 · D-2570, PlaceboInventisBio Co., LtdImmunology & inflammationPhase 2120Not sealed yet
Jul 30, 2026A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular CarcinomaNCT05320692 · TACE+Camrelizumab+Apatinib mesylate, TACEJiangsu HengRui Medicine Co., Ltd.OncologyPhase 3423Not sealed yet
Jul 30, 2026Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)NCT06940154 · Rademikibart in prefilled syringe, Matching placebo in prefilled syringeConnect Biopharm LLCRespiratoryPhase 2159Not sealed yet
Jul 31, 2026A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature InfantsNCT03253263 · OHB-607OHB Neonatology Ltd.OphthalmologyPhase 2295Not sealed yet
Jul 31, 2026INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted InfectionsNCT03037164 · INTERCEPT Blood System for Red Blood Cells, Conventional (Control)Cerus CorporationInfectious disease & vaccinesPhase 3692Not sealed yet
Jul 31, 2026Phase 3 Study of KP-100LI in Subjects With Vocal Fold ScarNCT05627648 · KP-100LI, PlaceboKringle Pharma, Inc.OtherPhase 362Not sealed yet
Jul 31, 2026A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseaseNCT06881836 · ONO-2020, PlaceboOno Pharmaceutical Co., Ltd.NeurologyPhase 2260Not sealed yet
Jul 31, 2026Determining the Potential for Efficacy of OTX-601 in Reducing PTSD SymptomsNCT07316088 · OTX-601 Digital Therapeutic, OTX-003 Comparator appOui Therapeutics, Inc.PsychiatryPhase 240Not sealed yet
Jul 31, 2026A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationNCT04639180 · Camrelizumab, Rivoceranib (Apatinib)Jiangsu HengRui Medicine Co., Ltd.OncologyPhase 3687Not sealed yet
Jul 31, 2026Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)NCT03711032 · Pembrolizumab, BCGMerck Sharp & Dohme LLCOncologyPhase 31,397Not sealed yet
Jul 31, 2026SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerNCT05445908 · SKB264, KL-A167Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.OncologyPhase 2184Not sealed yet
Jul 31, 2026A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of AgeNCT07300839 · BNT162b2 Vaccine, PlaceboBioNTech SEInfectious disease & vaccinesPhase 35,240Not sealed yet
Aug 2026A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.NCT03539744 · Pomalidomide, Dexamethasone, VenetoclaxAbbVieOncologyPhase 3265Not sealed yet
Aug 2026A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKNCT06556368 · Tarcocimab tedromer, Tabirafusp tedromer, AfliberceptKodiak Sciences IncOphthalmologyPhase 3675Not sealed yet
Aug 2026A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)NCT06382116 · BL-B01D1, Pemetrexed+Cisplatin or CarboplatinSichuan Baili Pharmaceutical Co., Ltd.OncologyPhase 3432Not sealed yet
Aug 2026A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)NCT07298330 · Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mgMirum Pharmaceuticals, Inc.Infectious disease & vaccinesPhase 380Not sealed yet
Aug 2026A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster VaccineNCT06581575 · JCXH-105, ShingrixImmorna Biotherapeutics, Inc.Infectious disease & vaccinesPhase 2467Not sealed yet
Aug 2026A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)NCT06343948 · BL-B01D1, Eribulin, VinorelbineSichuan Baili Pharmaceutical Co., Ltd.OncologyPhase 3383Not sealed yet
Aug 2026Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAENCT06669754 · Deucrictibant, PlaceboPharvaris Netherlands B.V.OtherPhase 381Not sealed yet
Aug 2026To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor ComplicationsNCT06553027 · CVN424 75 mg, CVN424 150 mg, PlaceboCerevanceNeurologyPhase 3330Not sealed yet
Aug 2026Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)NCT01983241 · Alpha-1 MP, 0.9% Sodium Chloride for Injection, USPGrifols Therapeutics LLCRespiratoryPhase 3345Not sealed yet
Aug 2026RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)NCT04514653 · Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2AbbVieOphthalmologyPhase 2146Not sealed yet
Aug 2026ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisNCT07011706 · ATI-045, PlaceboAclaris Therapeutics, Inc.Immunology & inflammationPhase 2110Not sealed yet
Aug 2026Aleniglipron Phase 2 Body Composition StudyNCT07169942 · aleniglipron or placeboGasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsDiabetes & obesityPhase 271Not sealed yet
Aug 2026A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)NCT07037875 · Linaprazan glurate 50 mg Twice Daily (BID), Linaprazan Glurate 50 mg Once Daily (QD), Lansoprazole 30 mg Once Daily (QD)Cinclus Pharma Holding ABOtherPhase 3500Not sealed yet
Aug 2026Study of VYD2311 for the Prevention of COVID-19NCT07298434 · VYD2311-SD, VYD2311-MD, PlaceboInvivyd, Inc.Infectious disease & vaccinesPhase 31,770Not sealed yet
Aug 2026Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931 · Selinexor, Matching Placebo for selinexorKaryopharm Therapeutics IncOncologyPhase 3257Not sealed yet
Aug 2026A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult ParticipantsNCT07032597 · HArmonyCa Lidocaine Injectable Gel, Restylane® Perlane® LidocaineAbbVieOtherPhase 3252Not sealed yet
Aug 1, 2026A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)NCT06767735 · GZR4, Insulin Glargine U100Gan & Lee Pharmaceuticals.Diabetes & obesityPhase 3580Not sealed yet
Aug 1, 2026Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaNCT06455059 · Vosoritide, PlaceboBioMarin PharmaceuticalOtherPhase 380Not sealed yet
Aug 2, 2026Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)NCT06829329 · AHB-137, NAs, PlaceboAusper Biopharma Co., Ltd.Infectious disease & vaccinesPhase 2105Not sealed yet
Aug 3, 2026A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)NCT07216482 · Enlicitide, Rosuvastatin, Placebo for EnlicitideMerck Sharp & Dohme LLCCardiovascularPhase 3996Not sealed yet
Aug 3, 2026Efficacy and Safety of CP006 Inhalation Powder in Participants With AsthmaNCT07807007 · Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide, Formoterol Fumarate, and Umeclidinium Bromide, Budesonide and Formoterol FumarateShanghai Xin Huanghe Pharmaceutical Co., Ltd.RespiratoryPhase 2150Not sealed yet
Aug 3, 2026A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)NCT06465186 · Efinopegdutide, PlaceboMerck Sharp & Dohme LLCLiverPhase 285Not sealed yet
Aug 5, 2026Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I DisorderNCT07046494 · RAP-219, PlaceboRapport Therapeutics Inc.PsychiatryPhase 2253Not sealed yet
Aug 5, 2026A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDGNCT06892288 · GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label)Glycomine, Inc.OtherPhase 2/350Not sealed yet
Aug 5, 2026A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac DiseaseNCT06557772 · Amlitelimab, Placebo, SIGESanofiOtherPhase 2229Not sealed yet
Aug 5, 2026A Study in Healthy Adults to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source and PlaceboNCT07241377 · life'sTM omega O1035DS nTG, life'sTM omega O3020DS nTG, MEG-3 3323rTGRDC Clinical Pty LtdOtherPhase 3120Not sealed yet
Aug 6, 2026This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightNCT07017179 · AZD6234, Placebo, AZD9550AstraZenecaDiabetes & obesityPhase 214Not sealed yet
Aug 6, 2026NE3107 in Adults With Neurological Symptoms of Long COVIDNCT06847191 · NE3107, PlaceboBioVie Inc.Infectious disease & vaccinesPhase 2203Not sealed yet
Aug 6, 2026A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative ColitisNCT06867094 · SAR441566, SAR441566 matching PlaceboSanofiImmunology & inflammationPhase 2204Not sealed yet
Aug 6, 2026A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis SubjectsNCT07357831 · MC2-01 cream, MC2-01 vehicle, CAL/BDP GelHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Immunology & inflammationPhase 3539Not sealed yet
Aug 6, 2026A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and InfantsNCT06213506 · iNTS-GMMA Dose C, iNTS-GMMA Dose B, iNTS-GMMA Dose AGlaxoSmithKlineInfectious disease & vaccinesPhase 2180Not sealed yet
Aug 7, 2026A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExerciseNCT06777238 · GZR18, PlaceboGan & Lee Pharmaceuticals.Diabetes & obesityPhase 3274Not sealed yet
Aug 7, 2026A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic DermatitisNCT06832618 · Ruxolitinib, Vehicle CreamIncyte CorporationImmunology & inflammationPhase 3159Not sealed yet
Aug 10, 2026Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System AtrophyNCT06671938 · exidavnemab, Placebo ComparatorBioArctic ABNeurologyPhase 238Not sealed yet
Aug 10, 2026A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCNCT05211895 · Durvalumab, Domvanalimab, PlaceboAstraZenecaOncologyPhase 3791Not sealed yet
Aug 10, 2026A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusNCT07321678 · ASC30 tablets, PlaceboAscletis Pharma (China) Co., LimitedDiabetes & obesityPhase 2100Not sealed yet
Aug 10, 2026Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyNCT06681324 · AZD7798, PlaceboAstraZenecaImmunology & inflammationPhase 224Not sealed yet
Aug 11, 2026Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)NCT06433219 · Tuvusertib (M1774), Niraparib, Lartesertib (M4076)EMD Serono Research & Development Institute, Inc.OncologyPhase 263Not sealed yet
Aug 11, 2026Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel DentifriceNCT07215767 · Stannous fluoride and Potassium nitrate Dentifrice, Stannous fluoride Dentifrice, Potassium nitrate DentifriceHALEONOtherPhase 3688Not sealed yet
Aug 12, 2026A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)NCT06018337 · DB-1303/BNT323, Capecitabine, PaclitaxelDualityBio Inc.OncologyPhase 3541Not sealed yet
Aug 12, 2026ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)NCT05601752 · Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with NivolumabUSWM CT, LLCOncologyPhase 266Not sealed yet
Aug 12, 2026A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)NCT06052059 · IV Tulisokibart, IV Placebo, SC TulisokibartMerck Sharp & Dohme LLCImmunology & inflammationPhase 31,109Not sealed yet
Aug 12, 2026Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal CandidiasisNCT07109869 · Boric acid, PlacebopH-D Feminine Health LLCOtherPhase 3333Not sealed yet
Aug 12, 2026To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisNCT06901505 · Erythropoiesis-Stimulating Agent (ESA), VadadustatAkebia TherapeuticsKidneyPhase 3353Not sealed yet
Aug 13, 2026A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)NCT06809595 · Placebo, DT120Definium Therapeutics US, Inc.PsychiatryPhase 3245Not sealed yet
Aug 13, 2026Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842 · Petrelintide, PlaceboZealand PharmaDiabetes & obesityPhase 2221Not sealed yet
Aug 14, 2026Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.NCT05267613 · Nexium 20mg, Nexium 10mgAstraZenecaOtherPhase 353Not sealed yet
Aug 14, 2026A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseaseNCT06926660 · Vicadrostat, Empagliflozin, Placebo matching vicadrostatBoehringer IngelheimKidneyPhase 2492Not sealed yet
Aug 14, 2026The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive SurgeryNCT06507436 · Herombopag tablets, Herombopag placebo tabletsJiangsu HengRui Medicine Co., Ltd.CardiovascularPhase 3127Not sealed yet
Aug 14, 2026A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU)NCT07372924 · Tegileridine Fumarate lnjection, Tegileridine Fumarate lnjection, Remifentanil Hydrochloride for InjectionJiangsu HengRui Medicine Co., Ltd.OtherPhase 2121Not sealed yet
Aug 17, 2026Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)NCT07016412 · Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcgVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USADiabetes & obesityPhase 2497Not sealed yet
Aug 17, 2026A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence SeizuresNCT06769659 · NPT 2042, PlaceboNeuroPro Therapeutics, Inc.NeurologyPhase 214Not sealed yet
Aug 17, 2026Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in ChildrenNCT03339128 · Eluxadoline, PlaceboAbbVieOtherPhase 2272Not sealed yet
Aug 18, 2026FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerNCT06519370 · FDA018-ADC, Eribulin, CapecitabineShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.OncologyPhase 3350Not sealed yet
Aug 18, 2026Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerNCT06619236 · Rina-S, Paclitaxel, TopotecanGenmabOncologyPhase 3584Not sealed yet
Aug 19, 2026A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1NCT06694805 · CAB LA + RPV LA, Oral ARTViiV HealthcareInfectious disease & vaccinesPhase 3326Not sealed yet
Aug 20, 2026Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsNCT05643534 · Tenapanor 50 MG, Tenapanor 25 mg bid, PlaceboArdelyxOtherPhase 3180Not sealed yet
Aug 20, 2026Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin SyndromeNCT06050122 · Patidegib Topical Gel, Patidegib Topical Gel with no active patidegibSol-Gel Technologies, Ltd.OncologyPhase 3113Not sealed yet
Aug 21, 2026Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)NCT07220629 · NT-0796, PlaceboRezera (formerly NodThera Limited)Diabetes & obesityPhase 282Not sealed yet
Aug 21, 2026A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseaseNCT07284381 · ABBV-444, REFRESH OPTIVE UDAbbVieOphthalmologyPhase 3261Not sealed yet
Aug 24, 2026A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and AboveNCT07204964 · Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A)GlaxoSmithKlineInfectious disease & vaccinesPhase 2971Not sealed yet
Aug 24, 2026A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441 · Fianlimab, Cemiplimab, PemetrexedRegeneron PharmaceuticalsOncologyPhase 2195Not sealed yet
Aug 26, 2026Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisNCT06468956 · SHR-1819, PlaceboGuangdong Hengrui Pharmaceutical Co., LtdImmunology & inflammationPhase 3652Not sealed yet
Aug 27, 2026Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 · Retatrutide, SemaglutideEli Lilly and CompanyDiabetes & obesityPhase 31,250Not sealed yet
Aug 28, 2026A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyNCT05568095 · Domvanalimab, Zimberelimab, CapecitabineArcus Biosciences, Inc.OncologyPhase 31,040Not sealed yet
Aug 30, 2026ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerNCT05446298 · ONC-392, PembrolizumabOncoC4, Inc.OncologyPhase 258Not sealed yet
Aug 30, 2026A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung CancerNCT07005336 · Uliledlimab, Sintilimab, PemetrexedTJ Biopharma Co., Ltd.OncologyPhase 2150Not sealed yet
Aug 30, 2026Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07108699 · HSK39004 Dry Powder Inhaler-0.75mg, HSK39004 Dry Powder Inhaler-1.5mg, HSK39004 Dry Powder Inhaler SimulantHaisco Pharmaceutical Group Co., Ltd.RespiratoryPhase 2180Not sealed yet
Aug 31, 2026A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic CancerNCT03816163 · zolbetuximab, nab-paclitaxel, gemcitabineAstellas Pharma Global Development, Inc.OncologyPhase 2393Not sealed yet
Aug 31, 2026A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaNCT06666855 · DE-117B Eye Drops, LatanoprostSanten Pharmaceutical Co., Ltd.OphthalmologyPhase 3345Not sealed yet
Aug 31, 2026Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular EdemaNCT06116916 · KHK4951, Aflibercept InjectionKyowa Kirin Co., Ltd.OphthalmologyPhase 2150Not sealed yet
Aug 31, 2026A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionNCT05797610 · Sefaxersen (RO7434656), PlaceboHoffmann-La RocheKidneyPhase 3459Not sealed yet
Aug 31, 2026Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) TrialNCT05408546 · TS23, PlaceboTranslational Sciences, Inc.CardiovascularPhase 264Not sealed yet
Aug 31, 2026LMN-201 for Prevention of C. Difficile Infection RecurrenceNCT05330182 · LMN-201, PlaceboLumen Bioscience, Inc.Infectious disease & vaccinesPhase 2/3375Not sealed yet
Aug 31, 2026Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)NCT04704934 · Trastuzumab deruxtecan, Ramucirumab, PaclitaxelDaiichi SankyoOncologyPhase 3490Not sealed yet
Aug 31, 2026Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)NCT06846515 · AR882 50 mg, AR882 75 mg, PlaceboArthrosi TherapeuticsImmunology & inflammationPhase 3866Not sealed yet
Aug 31, 2026A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)NCT06081894 · Aficamten, PlaceboCytokineticsCardiovascularPhase 3500Not sealed yet
Aug 31, 2026A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisNCT07225829 · 4P004, Placebo (NaCl 0.9%)4Moving BiotechImmunology & inflammationPhase 2129Not sealed yet
Aug 31, 2026Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular DegenerationNCT06116890 · KHK4951, Aflibercept InjectionKyowa Kirin Co., Ltd.OphthalmologyPhase 2180Not sealed yet
Aug 31, 2026A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)NCT06687369 · MB12 (Proposed Pembrolizumab Biosimilar), EU-sourced Keytruda®, US-sourced Keytruda®mAbxience Research S.L.OncologyPhase 3726Not sealed yet
Aug 31, 2026Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureNCT06935409 · HS-20093, Gemcitabine combined with docetaxelHansoh BioMedical R&D CompanyOncologyPhase 3117Not sealed yet
Sep 2026A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis PatientsNCT06292923 · Foralumab, PlaceboTiziana Life Sciences LTDNeurologyPhase 254Not sealed yet
Sep 2026A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic CardiomyopathyNCT07021976 · HRS-1893 Tablets, HRS-1893 Placebo TabletsShandong Suncadia Medicine Co., Ltd.CardiovascularPhase 3228Not sealed yet
Sep 2026Monthly Dosing of Atacicept in IgANNCT07020923 · AtaciceptVera Therapeutics, Inc.KidneyPhase 290Not sealed yet
Sep 2026A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)NCT06339008 · LY3650150, Placebo, Standard therapy for INCSEli Lilly and CompanyRespiratoryPhase 3450Not sealed yet
Sep 2026A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With HyperlipidemiaNCT07100418 · HRS-7249 Injection, Sodium Chloride InjectionFujian Shengdi Pharmaceutical Co., Ltd.OtherPhase 2224Not sealed yet
Sep 2026Study of Bitopertin in Participants With EPP or XLP (APOLLO)NCT06910358 · Placebo, DISC-1459Disc Medicine, IncOtherPhase 3183Not sealed yet
Sep 2026Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)NCT04652882 · Tasimelteon, PlaceboVanda PharmaceuticalsOtherPhase 370Not sealed yet
Sep 2026Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or ObesityNCT07804797 · MWN109 1, MWN109 2Shanghai Minwei Biotechnology Co., LtdDiabetes & obesityPhase 271Not sealed yet
Sep 2026A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870 · Selinexor, Physician's Choice TreatmentKaryopharm Therapeutics IncOtherPhase 2112Not sealed yet
Sep 2026A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye DiseaseNCT06088979 · TOUR006 - 20 MG, Placebo, TOUR006 - 50 MGTourmaline Bio, Inc., a Novartis CompanyOphthalmologyPhase 279Not sealed yet
Sep 2026Clinical Study of Neflamapimod in Patients With Primary Progressive AphasiaNCT07033481 · Neflamapimod, PlaceboEIP Pharma IncOtherPhase 220Not sealed yet
Sep 2026Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionNCT02932150 · TAF, PlaceboGilead SciencesInfectious disease & vaccinesPhase 2150Not sealed yet
Sep 2026A Study of Obexelimab in Patients With Systemic Lupus ErythematosusNCT06559163 · Obexelimab, PlaceboZenas BioPharma (USA), LLCImmunology & inflammationPhase 2190Not sealed yet
Sep 2026A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor NeuropathyNCT06742190 · Empasiprubart, IVIG (Intravenous Immunoglobulin), Empasiprubart-placeboargenxNeurologyPhase 3154Not sealed yet
Sep 2026MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT06132256 · Axatilimab, PlaceboSyndax PharmaceuticalsRespiratoryPhase 2145Not sealed yet
Sep 2026Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis DNCT06649266 · RBD1016, PlaceboRibocure Pharmaceuticals ABInfectious disease & vaccinesPhase 214Not sealed yet
Sep 2026C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVNCT06868264 · Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL)Atea Pharmaceuticals, Inc.Infectious disease & vaccinesPhase 3880Not sealed yet
Sep 2026Aleniglipron Phase 2 in Type 2 Diabetes MellitusNCT07400588 · Aleniglipron, PlaceboGasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsDiabetes & obesityPhase 258Not sealed yet
Sep 2026Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress IncontinenceNCT03104517 · AMDC-USR (iltamiocel), PlaceboCook MyoSiteOtherPhase 396Not sealed yet
Sep 2026Taldefgrobep Alfa in Adults With Overweight and ObesityNCT07281495 · Taldefgrobep Alfa, Placebo, Taldefgrobep AlfaBiohaven Therapeutics Ltd.Diabetes & obesityPhase 2150Not sealed yet
Sep 1, 2026Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsNCT04824092 · Tafasitamab, Lenalidomide, RituximabIncyte CorporationOncologyPhase 3899Not sealed yet
Sep 2, 2026Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseNCT04691661 · Radotinib HCl 50 mg, PlaceboIl-Yang Pharm. Co., Ltd.NeurologyPhase 243Not sealed yet
Sep 3, 2026Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerNCT05132075 · JDQ443, docetaxelNovartis PharmaceuticalsOncologyPhase 395Not sealed yet
Sep 3, 2026A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityNCT06965413 · RO7204239, RO7204239 Matching Placebo, TirzepatideHoffmann-La RocheDiabetes & obesityPhase 2285Not sealed yet
Sep 4, 2026"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · CYB003, Psychological Support, PlaceboCybin IRL LimitedPsychiatryPhase 3220Not sealed yet
Sep 4, 2026Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusNCT05039840 · SAR441344 IV, SAR441344 SC, Placebo IVSanofiImmunology & inflammationPhase 2109Not sealed yet
Sep 6, 2026A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65NCT07060885 · HDM SLIT-tablet (12 SQ-HDM), PlaceboALK-Abelló A/SOphthalmologyPhase 3327Not sealed yet
Sep 6, 2026IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaNCT07473960 · IBI306, placebo, placeboInnovent Biologics (Suzhou) Co. Ltd.CardiovascularPhase 3198Not sealed yet
Sep 6, 2026Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated AdultsNCT07215520 · NDV-HXP-S-KP.2, COVID-19 mRNA VaccineCastleVax Inc.Infectious disease & vaccinesPhase 2200Not sealed yet
Sep 7, 2026Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)NCT05291091 · Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mgEdgewise Therapeutics, Inc.OtherPhase 2244Not sealed yet
Sep 7, 2026A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)NCT07176390 · Tulisokibart, Placebo, MethotrexateMerck Sharp & Dohme LLCImmunology & inflammationPhase 2185Not sealed yet
Sep 9, 2026A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)NCT06741397 · CAB LA, New formulation of CAB LAViiV HealthcareInfectious disease & vaccinesPhase 2229Not sealed yet
Sep 10, 2026A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDNCT06208306 · Itepekimab (SAR440340), PlaceboSanofiRespiratoryPhase 3669Not sealed yet
Sep 10, 2026A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202NCT06062420 · Dostarlimab, Belrestotug, NelistotugGlaxoSmithKlineOncologyPhase 2316Not sealed yet
Sep 11, 2026A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior UveitisNCT06431373 · Brepocitinib PO QD, Placebo PO QDPriovant Therapeutics, Inc.OphthalmologyPhase 3371Not sealed yet
Sep 15, 2026A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac DiseaseNCT06807463 · TEV-53408, PlaceboTeva Branded Pharmaceutical Products R&D LLCOtherPhase 250Not sealed yet
Sep 15, 2026A Study to Evaluate Efficacy and Safety of GW906 in Patients With Essential HypertensionNCT07835971 · GW906, PlaceboShenzhen Salubris Pharmaceuticals Co., Ltd.CardiovascularPhase 2319Not sealed yet
Sep 17, 2026A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)NCT07074886 · Ocrelizumab Test Formulation, Ocrelizumab Reference FormulationHoffmann-La RocheNeurologyPhase 2193Not sealed yet
Sep 18, 2026Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide PolymorphismsNCT07145333 · Topotecan - usual, Topotecan - studyHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairOtherPhase 2/3600Not sealed yet
Sep 24, 2026A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityNCT06862908 · placebo, IBI362Innovent Biologics (Suzhou) Co. Ltd.Diabetes & obesityPhase 2141Not sealed yet
Sep 26, 2026A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High ProteinuriaNCT06942910 · Zibotentan/Dapagliflozin, DapagliflozinAstraZenecaKidneyPhase 2224Not sealed yet
Sep 27, 2026A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04961567 · Litifilimab, PlaceboBiogenImmunology & inflammationPhase 3562Not sealed yet
Sep 28, 2026A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaNCT05888844 · INCB099280Incyte CorporationOncologyPhase 263Not sealed yet
Sep 28, 2026A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt DiseaseNCT05956626 · OCU410STOcugenOphthalmologyPhase 2/351Not sealed yet
Sep 28, 2026A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)NCT05552976 · Mezigdomide, Carfilzomib, DexamethasoneBristol-Myers SquibbOncologyPhase 3606Not sealed yet
Sep 29, 2026Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)NCT05263934 · Depemokimab, Mepolizumab, Placebo matching mepolizumabGlaxoSmithKlineImmunology & inflammationPhase 3163Not sealed yet
Sep 30, 2026A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast CancerNCT07192588 · GR1014-CG 2.4%, Vehicle Gel, Radiation TherapyGraegis Pharmaceuticals LtdOncologyPhase 2273Not sealed yet
Sep 30, 2026A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMENCT06571045 · Ranibizumab, EYE103EyeBiotech Ltd.OphthalmologyPhase 2/3984Not sealed yet
Sep 30, 2026A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With DyslipidaemiaNCT07218900 · Placebo, AZD0780, RosuvastatinAstraZenecaCardiovascularPhase 276Not sealed yet
Sep 30, 2026Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerNCT05116462 · Pemetrexed, Carboplatin, PaclitaxelInnovent Biologics (Suzhou) Co. Ltd.OncologyPhase 3506Not sealed yet
Sep 30, 2026A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesNCT04603807 · Entrectinib, CrizotinibHoffmann-La RocheOncologyPhase 3217Not sealed yet
Sep 30, 2026A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationNCT05230537 · Iptacopan (LNP023), PlaceboNovartis PharmaceuticalsOphthalmologyPhase 2168Not sealed yet
Sep 30, 2026A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveNCT05879822 · INCB099280Incyte CorporationOncologyPhase 273Not sealed yet
Sep 30, 2026A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusNCT04895241 · Litifilimab, PlaceboBiogenImmunology & inflammationPhase 3548Not sealed yet
Sep 30, 2026A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic StrokeNCT06987643 · Neflamapimod, PlaceboEIP Pharma IncCardiovascularPhase 290Not sealed yet
Sep 30, 2026A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent WheezingNCT05857930 · OM-85, PlaceboOM Pharma SAOtherPhase 2296Not sealed yet
Sep 30, 2026An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 StudyNCT06534892 · RSVPreF3 OA vaccineGlaxoSmithKlineInfectious disease & vaccinesPhase 310,212Not sealed yet
Sep 30, 2026A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840 · Durvalumab, Oleclumab, MonalizumabAstraZenecaOncologyPhase 31,051Not sealed yet
Sep 30, 2026A Study to Evaluate Solrikitug in Participants With COPD (ZION)NCT06496620 · Biological: Solrikitug low dose, Biological: Solrikitug high dose, PlaceboUniquity One (UNI)RespiratoryPhase 2182Not sealed yet
Oct 2026Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603 · Retatrutide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3320Not sealed yet
Oct 2026AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerNCT06591520 · AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, CisplatinAkesoOncologyPhase 3682Not sealed yet
Oct 2026Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMDNCT05407636 · ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)AbbVieOphthalmologyPhase 3735Not sealed yet
Oct 2026Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)NCT06553768 · Maralixibat, PlaceboMirum Pharmaceuticals, Inc.OtherPhase 390Not sealed yet
Oct 2026A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173 · sabirnetug, PlaceboAcumen PharmaceuticalsNeurologyPhase 2542Not sealed yet
Oct 2026A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaNCT06445023 · barzolvolimab, Matching placeboCelldex TherapeuticsImmunology & inflammationPhase 3963Not sealed yet
Oct 2026A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)NCT04088396 · Baricitinib, TocilizumabEli Lilly and CompanyImmunology & inflammationPhase 358Not sealed yet
Oct 2026A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)NCT04965493 · Pirtobrutinib, Venetoclax, RituximabLoxo Oncology, Inc.OncologyPhase 3600Not sealed yet
Oct 2026A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)NCT06980805 · IMVT-1402, PlaceboImmunovant Sciences GmbHImmunology & inflammationPhase 256Not sealed yet
Oct 2026Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With OverweightNCT07791537 · MWN109 1, MWN109 2, MWN109 3Shanghai Minwei Biotechnology Co., LtdDiabetes & obesityPhase 2125Not sealed yet
Oct 2026Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic AlopeciaNCT05888922 · Minoxidil Tablets, Minoxidil Topical, Placebo oral tabletIndustrial Farmacéutica Cantabria, S.A.Immunology & inflammationPhase 3520Not sealed yet
Oct 2026A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)NCT07210463 · NT 201, NT 201 PlaceboMerz Aesthetics GmbHOtherPhase 3300Not sealed yet
Oct 2026Evaluate the Safety and Efficacy of TJO-087NCT07810972 · TJO-087, TJO-087, Vehicle (Placebo solution)Taejoon Pharmaceutical Co., Ltd.OphthalmologyPhase 290Not sealed yet
Oct 2026Dazucorilant in Patients With Amyotrophic Lateral SclerosisNCT05407324 · Dazucorilant 300 mg, Dazucorilant 150 mg, PlaceboCorcept TherapeuticsNeurologyPhase 2279Not sealed yet
Oct 2026A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56NCT06683742 · EYP-1901, Aflibercept (2.0 mg)EyePoint Pharmaceuticals, Inc.OphthalmologyPhase 3400Not sealed yet
Oct 2026A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)NCT06455202 · barzolvolimab, Matching placeboCelldex TherapeuticsImmunology & inflammationPhase 3976Not sealed yet
Oct 2026A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksNCT06851559 · Vonoprazan, PlaceboPhathom Pharmaceuticals, Inc.OtherPhase 295Not sealed yet
Oct 2026Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyNCT06309966 · BHV-7000, BHV-7000, PlaceboBiohaven Therapeutics Ltd.NeurologyPhase 2/3390Not sealed yet
Oct 2026A Study Evaluating TRIV-509 in Atopic DermatitisNCT07167758 · TRIV-509, PlaceboTriveni BioImmunology & inflammationPhase 295Not sealed yet
Oct 2026A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)NCT06422884 · ENV-101, PlaceboEndeavor Biomedicines, Inc.RespiratoryPhase 2213Not sealed yet
Oct 2026HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.NCT07233070 · HRS-7450 Injection, HRS-7450 Injection, HRS-7450 InjectionFujian Shengdi Pharmaceutical Co., Ltd.CardiovascularPhase 2210Not sealed yet
Oct 2026Effect of 10 mg Xanamem on Dementia Due to Alzheimer's DiseaseNCT06125951 · Xanamem, PlaceboActinogen MedicalNeurologyPhase 2/3247Not sealed yet
Oct 2026A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerNCT06316531 · BL-M07D1, T-DM1Sichuan Baili Pharmaceutical Co., Ltd.OncologyPhase 3274Not sealed yet
Oct 1, 2026A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminNCT06257966 · Exendin-4 Fc fusion protein injection(1.2mg）, Exendin-4 Fc fusion protein injection（2.4mg）, DulaglutideBeijing Dongfang Biotech Co., Ltd.Diabetes & obesityPhase 3600Not sealed yet
Oct 1, 2026A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNCT06200207 · Ziltivekimab, PlaceboNovo Nordisk A/SCardiovascularPhase 3680Not sealed yet
Oct 2, 2026A Trial of TAK-861 for the Treatment of Narcolepsy With CataplexyNCT07363720 · TAK-861, PlaceboTakedaOtherPhase 398Not sealed yet
Oct 5, 2026A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisNCT03165734 · Pacritinib, Physician's Choice medicationsSwedish Orphan BiovitrumCardiovascularPhase 3407Not sealed yet
Oct 6, 2026A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisNCT06003426 · BMS-986278, BMS-986278 PlaceboBristol-Myers SquibbRespiratoryPhase 31,255Not sealed yet
Oct 8, 2026A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaNCT05805501 · Tobemstomig, Tiragolumab, PembrolizumabHoffmann-La RocheOncologyPhase 2199Not sealed yet
Oct 9, 2026Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)NCT06958211 · Ruxolitinib Cream, Vehicle CreamIncyte CorporationImmunology & inflammationPhase 3573Not sealed yet
Oct 9, 2026Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)NCT06959225 · Ruxolitinib Cream, Vehicle CreamIncyte CorporationImmunology & inflammationPhase 3580Not sealed yet
Oct 12, 2026A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentNCT05133531 · Ravulizumab, Pozelimab, CemdisiranRegeneron PharmaceuticalsHematologyPhase 3202Not sealed yet
Oct 12, 2026A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPCNCT05884398 · Apalutamide, Androgen-deprivation Therapy (ADT)Janssen Research & Development, LLCOncologyPhase 3420Not sealed yet
Oct 13, 2026Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPFNCT05389215 · DWN12088, PlaceboDaewoong Pharmaceutical Co. LTD.RespiratoryPhase 2102Not sealed yet
Oct 14, 2026A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834347 · Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)SanofiRespiratoryPhase 3231Not sealed yet
Oct 14, 2026A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabNCT04770896 · Atezolizumab, Lenvatinib, SorafenibHoffmann-La RocheOncologyPhase 3557Not sealed yet
Oct 15, 2026Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian CancerNCT05605535 · Oregovomab, Paclitaxel, CarboplatinCanariaBio Inc.OncologyPhase 288Not sealed yet
Oct 15, 2026A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKENCT05702034 · Milvexian, PlaceboJanssen Research & Development, LLCCardiovascularPhase 312,523Not sealed yet
Oct 15, 2026An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCNCT06894511 · AAA617, ARPI: Abiraterone, ARPI: EnzalutamideNovartis PharmaceuticalsOncologyPhase 27Not sealed yet
Oct 15, 2026Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsNCT06569108 · KN057Suzhou Alphamab Co., Ltd.HematologyPhase 3125Not sealed yet
Oct 15, 2026MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) TrialNCT07505303 · ECC4703, Placebo, SemaglutideEccogeneDiabetes & obesityPhase 2151Not sealed yet
Oct 18, 2026Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled CancersNCT07033585 · Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetesHan Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairOncologyPhase 2/3600Not sealed yet
Oct 19, 2026A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)NCT06516952 · Povorcitinib, PlaceboIncyte CorporationOtherPhase 3349Not sealed yet
Oct 19, 2026A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)NCT05617677 · Deucravacitinib, PlaceboBristol-Myers SquibbImmunology & inflammationPhase 3516Not sealed yet
Oct 19, 2026A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusNCT05620407 · Deucravacitinib, PlaceboBristol-Myers SquibbImmunology & inflammationPhase 3513Not sealed yet
Oct 19, 2026A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerNCT05852691 · Tobemstomig, Pembrolizumab, Nab-PaclitaxelHoffmann-La RocheOncologyPhase 283Not sealed yet
Oct 19, 2026A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)NCT06516965 · Povorcitinib, PlaceboIncyte CorporationOtherPhase 3346Not sealed yet
Oct 20, 2026A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusNCT05531565 · Litifilimab, PlaceboBiogenImmunology & inflammationPhase 2/3450Not sealed yet
Oct 22, 2026A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom StateNCT06245408 · Dazodalibep, PlaceboAmgenImmunology & inflammationPhase 3434Not sealed yet
Oct 23, 2026A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASNCT06008093 · Durvalumab, Tremelimumab, PemetrexedAstraZenecaOncologyPhase 2103Not sealed yet
Oct 26, 2026Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular EventsNCT05360446 · Inclisiran sodium 300 mg, PlaceboNovartis PharmaceuticalsCardiovascularPhase 3609Not sealed yet
Oct 28, 2026A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyNCT05115110 · RO7204239, Placebo, RisdiplamHoffmann-La RocheRare genetic diseasePhase 2/397Not sealed yet
Oct 28, 2026A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)NCT05239728 · Belzutifan, Pembrolizumab, PlaceboMerck Sharp & Dohme LLCOncologyPhase 31,800Not sealed yet
Oct 28, 2026A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyNCT06722157 · BI 771716, Pegcetacoplan, Sham comparator to BI 771716Boehringer IngelheimOphthalmologyPhase 2202Not sealed yet
Oct 29, 2026Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaNCT05928390 · Pasireotide DiaspartateRECORDATI GROUPDiabetes & obesityPhase 293Not sealed yet
Oct 29, 2026Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)NCT05653349 · Ianalumab, Placebo, CorticosteroidsNovartis PharmaceuticalsCardiovascularPhase 3226Not sealed yet
Oct 30, 2026A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaNCT04657991 · Encorafenib, Binimetinib, PembrolizumabPfizerOncologyPhase 3257Not sealed yet
Oct 30, 2026A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 DiabetesNCT07026968 · Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR, Prusogliptin, Dapagliflozin(high dose) placebo, Dapagliflozin (low dose), plus metformin XRCSPC Ouyi Pharmaceutical Co., Ltd.Diabetes & obesityPhase 3815Not sealed yet
Oct 30, 2026Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast CancerNCT04851613 · Afuresertib, Afuresertib/placeboLaekna LimitedOncologyPhase 3256Not sealed yet
Oct 30, 2026A Study of VCT220 in Participants With Hypertension and Obesity or OverweightNCT07360275 · VCT220 Tablet, VCT220 Placebo TabletVincentage Pharma Co., LtdDiabetes & obesityPhase 2160Not sealed yet
Oct 30, 2026Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)NCT05853575 · AdagrasibMirati Therapeutics Inc.OncologyPhase 2200Not sealed yet
Oct 31, 2026A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)NCT07211633 · Ublituximab, UblituximabTG Therapeutics, Inc.NeurologyPhase 3360Not sealed yet
Oct 31, 2026Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart FailureNCT05598333 · AB-1002AskBio IncCardiovascularPhase 2150Not sealed yet
Oct 31, 2026A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)NCT03992430 · EteplirsenSarepta Therapeutics, Inc.Rare genetic diseasePhase 3160Not sealed yet
Oct 31, 2026Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeNCT04842617 · SHR6390, placeboJiangsu HengRui Medicine Co., Ltd.OncologyPhase 35,274Not sealed yet
Oct 31, 2026A Study of SPY072 in Rheumatic DiseaseNCT07148414 · SPY002-072, PlaceboSpyre Therapeutics, Inc.Immunology & inflammationPhase 2285Not sealed yet
Oct 31, 2026A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)NCT06593522 · anvumetostatAmgenOncologyPhase 261Not sealed yet
Oct 31, 2026OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · Palazestrant, Fulvestrant, AnastrozoleOlema Pharmaceuticals, Inc.OncologyPhase 3510Not sealed yet
Oct 31, 2026A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)NCT06510816 · Vonaprument, Sham AdministrationAnnexon, Inc.OphthalmologyPhase 3659Not sealed yet
Oct 31, 2026Study of JK07 in Patients With Chronic Heart FailureNCT06369298 · JK07, PlaceboSalubris Biotherapeutics IncCardiovascularPhase 2282Not sealed yet
Oct 31, 2026A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)NCT06719141 · LP352, PlaceboLongboard PharmaceuticalsNeurologyPhase 3367Not sealed yet
Oct 31, 2026TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNCT04129502 · TAK-788, Pemetrexed, CisplatinTakedaOncologyPhase 3354Not sealed yet
Oct 31, 2026A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsNCT06052267 · TEV-56248, Albuterol sulfateTeva Branded Pharmaceutical Products R&D LLCRespiratoryPhase 32,772Not sealed yet
Nov 2026A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNCT06111235 · Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltosideCG Oncology, Inc.OncologyPhase 3367Not sealed yet
Nov 2026A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightNCT06914895 · Tirzepatide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3905Not sealed yet
Nov 2026A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisNCT06736990 · CAL101, PlaceboCalluna Pharma ASRespiratoryPhase 2150Not sealed yet
Nov 2026A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaNCT06843590 · ALKS 2680, PlaceboAlkermes, Inc.OtherPhase 2126Not sealed yet
Nov 2026A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightNCT06962280 · Tirzepatide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3465Not sealed yet
Nov 2026A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute PyelonephritisNCT06569056 · HRS-8427, Imipenem and Cilastatin Sodium, HRS-8427 placeboJiangsu HengRui Medicine Co., Ltd.KidneyPhase 3579Not sealed yet
Nov 2026A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionNCT07142811 · Tobevibart, Elebsiran, BulevirtideVir Biotechnology, Inc.Infectious disease & vaccinesPhase 2100Not sealed yet
Nov 2026A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal CancerNCT04486378 · RO7198457 intravenous (IV), Observational group (no intervention)BioNTech SEOncologyPhase 2327Not sealed yet
Nov 2026A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CFNCT06237335 · RCT2100, Placebo, RCT2100ReCode TherapeuticsRespiratoryPhase 2128Not sealed yet
Nov 2026A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06448312 · SKB264, PembrolizumabSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.OncologyPhase 3406Not sealed yet
Nov 2026Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05201638 · IMU-838 tablets, Placebo matching IMU-838 tabletsImmunic AGNeurologyPhase 31,100Not sealed yet
Nov 2026A Study Evaluating APG777 in Atopic DermatitisNCT06395948 · APG777, PlaceboApogee Therapeutics, Inc.Immunology & inflammationPhase 2470Not sealed yet
Nov 2026To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis.NCT07605338 · Colgate SNaP Total 10/10, 1.5 Taurate, Colgate Great Regular Flavor Toothpaste, Flat Trimmed Extra Clean TBColgate PalmoliveOtherPhase 385Not sealed yet
Nov 2026Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)NCT05822752 · Budigalimab, Livmoniplimab, LenvatinibAbbVieOncologyPhase 2130Not sealed yet
Nov 2026A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With DermatomyositisNCT06284954 · Empasiprubart IV, Placebo IVargenxOtherPhase 23Not sealed yet
Nov 2026A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETNCT05050942 · CAM2029, Octreotide LAR, Lanreotide ATGCamurus ABOncologyPhase 3332Not sealed yet
Nov 2026Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610 · Tibulizumab Dose A, Tibulizumab Dose B, PlaceboZura Bio IncImmunology & inflammationPhase 2225Not sealed yet
Nov 2026A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal InsulinNCT07215312 · LY3938577, DegludecEli Lilly and CompanyDiabetes & obesityPhase 2100Not sealed yet
Nov 2026A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)NCT06118333 · BL-B01D1, capecitabine, gemcitabineSichuan Baili Pharmaceutical Co., Ltd.OncologyPhase 3386Not sealed yet
Nov 2026A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 · Retatrutide, TirzepatideEli Lilly and CompanyDiabetes & obesityPhase 3800Not sealed yet
Nov 2026Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisNCT05134441 · IMU-838 tablets, Placebo matching IMU-838 tabletsImmunic AGNeurologyPhase 31,121Not sealed yet
Nov 2026Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseaseNCT05202509 · Obicetrapib, PlaceboNewAmsterdam PharmaCardiovascularPhase 39,541Not sealed yet
Nov 2026Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationNCT06106308 · Onvansertib, FOLFIRI, BevacizumabCardiff OncologyOncologyPhase 2110Not sealed yet
Nov 2026Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisNCT06847724 · CYB704, Ocrevus-EU, Ocrevus-USSandozNeurologyPhase 3183Not sealed yet
Nov 2026Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)NCT07003919 · DBV712 250 mcg, PlaceboDBV TechnologiesRespiratoryPhase 3480Not sealed yet
Nov 2026A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)NCT06355531 · FNP-223, PlaceboFerrer Internacional S.A.OtherPhase 2241Not sealed yet
Nov 2026A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaNCT06637501 · Sonrotoclax, ZanubrutinibBeOne MedicinesOncologyPhase 294Not sealed yet
Nov 2026Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 YearsNCT07505888 · experimental vaccine, active comparator vaccineSinovac Biotech Co., LtdInfectious disease & vaccinesPhase 3660Not sealed yet
Nov 2, 2026A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusNCT06015737 · Anifrolumab, PlaceboAstraZenecaImmunology & inflammationPhase 3339Not sealed yet
Nov 2, 2026A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaNCT06190951 · cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, PlaceboRegeneron PharmaceuticalsOncologyPhase 2151Not sealed yet
Nov 3, 202624 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-upNCT05677451 · LOU064 (blinded), placeboNovartis PharmaceuticalsImmunology & inflammationPhase 3100Not sealed yet
Nov 6, 2026A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834360 · Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)SanofiRespiratoryPhase 3216Not sealed yet
Nov 9, 2026A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerNCT05565378 · Pembrolizumab, Dostarlimab, BelrestotugGlaxoSmithKlineOncologyPhase 2351Not sealed yet
Nov 10, 2026LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.NCT06351020 · LM-302, Apatinib, IrinotecanLaNova Medicines Zhejiang Co., Ltd.OncologyPhase 3387Not sealed yet
Nov 11, 2026Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)NCT04784715 · Trastuzumab deruxtecan, Placebo, TaxaneAstraZenecaOncologyPhase 31,157Not sealed yet
Nov 13, 2026Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USNCT07431086 · Olatorepatide, PlaceboRegeneron PharmaceuticalsDiabetes & obesityPhase 2120Not sealed yet
Nov 15, 2026Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular HypertensionNCT06964191 · PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic SolutionPolyActiva Pty LtdOphthalmologyPhase 275Not sealed yet
Nov 18, 2026A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeNCT05946941 · Deucravacitinib, PlaceboBristol-Myers SquibbImmunology & inflammationPhase 3774Not sealed yet
Nov 18, 2026Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide PolymorphismsNCT03348670 · Abiraterone - Usual, Abiraterone - StudyHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairOncologyPhase 2/3600Not sealed yet
Nov 18, 2026Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide PolymorphismsNCT01064466 · ETOPOSIDE - Usual, ETOPOSIDE - StudyHan Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairOncologyPhase 2/3600Not sealed yet
Nov 19, 2026A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)NCT06402838 · RO7269162, PlaceboHoffmann-La RocheNeurologyPhase 2256Not sealed yet
Nov 19, 2026A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisNCT07230860 · JNJ-95597528, PlaceboJanssen Research & Development, LLCImmunology & inflammationPhase 2189Not sealed yet
Nov 20, 2026Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)NCT04634877 · Pembrolizumab, Carboplatin, PaclitaxelMerck Sharp & Dohme LLCOncologyPhase 3990Not sealed yet
Nov 20, 2026A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaNCT05851443 · povorcitinib, placebo, ICS-LABAIncyte CorporationRespiratoryPhase 2247Not sealed yet
Nov 20, 2026Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboNCT06577090 · Nimacimab injection, Nimacimab placebo injection, semaglutide injectionSkye Bioscience, Inc.Diabetes & obesityPhase 2136Not sealed yet
Nov 24, 2026A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)NCT06616974 · TX000045- Dose A, TX000045- Dose B, PlaceboTectonic TherapeuticCardiovascularPhase 2191Not sealed yet
Nov 26, 2026A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerNCT03981796 · Dostarlimab, Placebo matching dostarlimab, CarboplatinTesaro, Inc.OncologyPhase 3785Not sealed yet
Nov 27, 2026A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872 · RO7795081, Semaglutide, PlaceboHoffmann-La RocheDiabetes & obesityPhase 2240Not sealed yet
Nov 28, 2026A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's DiseaseNCT06773962 · TB006, PlaceboTrueBinding, Inc.NeurologyPhase 262Not sealed yet
Nov 30, 2026A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsNCT07656727 · Oral BGE-102, Oral Placebo Matching BGE-102BioAge Labs, Inc.Diabetes & obesityPhase 2160Not sealed yet
Nov 30, 2026A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane TherapyNCT06968585 · A166, T-DM1Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.OncologyPhase 3365Not sealed yet
Nov 30, 2026RNS System LGS Feasibility StudyNCT05339126 · RNS SystemNeuroPaceNeurologyPhase 224Not sealed yet
Nov 30, 2026Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production CellsNCT07199569 · Jynneos, MVA-BN (Quail)Bavarian NordicInfectious disease & vaccinesPhase 2970Not sealed yet
Nov 30, 2026A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07553299 · VRB-101, PlaceboVerdiva Bio Dev LimitedDiabetes & obesityPhase 2120Not sealed yet
Dec 2026C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVNCT07037277 · Bemnifosbuvir-Ruzasvir, Sofosbuvir-VelpatasvirAtea Pharmaceuticals, Inc.Infectious disease & vaccinesPhase 3880Not sealed yet
Dec 2026A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)NCT04344158 · AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate TabletsChia Tai Tianqing Pharmaceutical Group Co., Ltd.OncologyPhase 3648Not sealed yet
Dec 2026A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic AgentsNCT07472725 · SHR-3167 Injection, SHR-3167 Injection PlaceboJiangsu HengRui Medicine Co., Ltd.Diabetes & obesityPhase 2102Not sealed yet
Dec 2026A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)NCT06500026 · BL-B01D1, TopotecanSichuan Baili Pharmaceutical Co., Ltd.OncologyPhase 3722Not sealed yet
Dec 2026A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)NCT06577935 · AGA2118, PlaceboAngitia BiopharmaceuticalsEndocrine & bonePhase 2379Not sealed yet
Dec 2026A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06711900 · SKB264, Pembrolizumab, pemetrexedSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.OncologyPhase 3432Not sealed yet
Dec 2026Safety and Efficacy of VDPHL01 in Males With AGANCT06972264 · VDPHL01, PlaceboVeradermics, Inc.Immunology & inflammationPhase 3480Not sealed yet
Dec 2026ZILRETTA in Subjects With Shoulder OsteoarthritisNCT06269705 · ZILRETTA, PlaceboPacira Pharmaceuticals, IncImmunology & inflammationPhase 3150Not sealed yet
Dec 2026Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric InjuryNCT05776277 · Iltamiocel, PlaceboCook MyoSiteOtherPhase 3200Not sealed yet
Dec 2026Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and BevacizumabNCT06107413 · ABBV-400, Bevacizumab, Folinic AcidAbbVieOncologyPhase 2280Not sealed yet
Dec 2026A Study of SHJ002 Sterile Ophthalmic Solution for Myopia ControlNCT06579287 · SHJ002, AtropineSunhawk Vision Biotech, Inc.OphthalmologyPhase 2140Not sealed yet
Dec 2026Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)NCT07074977 · nemolizumab, PlaceboGalderma R&DOtherPhase 250Not sealed yet
Dec 2026A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLCNCT06671379 · SHR-A2009 monotherapy, platinum-based dual-agent chemotherapySuzhou Suncadia Biopharmaceuticals Co., Ltd.OncologyPhase 3498Not sealed yet
Dec 2026A Study of Navenibart in Participants With Hereditary AngioedemaNCT06842823 · navenibart, PlaceboAstria Therapeutics, Inc.OtherPhase 3157Not sealed yet
Dec 2026Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic PainNCT06848348 · Halneuron, Placebo, Halneuron (Open Label Extension)Dogwood Therapeutics Inc.NeurologyPhase 2240Not sealed yet
Dec 2026Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoENCT06596252 · BudesonideDr. Falk Pharma GmbHOtherPhase 3308Not sealed yet
Dec 2026A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideNCT07128550 · Tobevibart, Elebsiran, BulevirtideVir Biotechnology, Inc.Infectious disease & vaccinesPhase 3150Not sealed yet
Dec 2026Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)NCT06912633 · human retinal progenitor cells, Mock injectionjCyte, IncOphthalmologyPhase 231Not sealed yet
Dec 2026Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NCT02227251 · Selinexor, Selinexor, SelinexorKaryopharm Therapeutics IncOncologyPhase 2244Not sealed yet
Dec 2026A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.NCT05987358 · TQB3454 tablets, TQB3454 tablets matching placeboChia Tai Tianqing Pharmaceutical Group Co., Ltd.OncologyPhase 3165Not sealed yet
Dec 2026A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor NeuropathyNCT06537999 · Claseprubart, PlaceboDianthus TherapeuticsNeurologyPhase 246Not sealed yet
Dec 2026Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)NCT06721871 · Crofelemer Powder for Oral Solution, Placebo Powder for Oral SolutionNapo Pharmaceuticals, Inc.OtherPhase 2/36Not sealed yet
Dec 2026A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)NCT06382129 · BL-B01D1, DocetaxelSichuan Baili Pharmaceutical Co., Ltd.OncologyPhase 3698Not sealed yet
Dec 2026A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)NCT05500222 · Resmetirom, PlaceboMadrigal Pharmaceuticals, Inc.LiverPhase 3845Not sealed yet
Dec 2026Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate HypertensionNCT07297797 · HRS-9563 Injection, sodium chloride injectionFujian Shengdi Pharmaceutical Co., Ltd.CardiovascularPhase 2238Not sealed yet
Dec 2026Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypeNCT05397639 · Masupirdine 50 mg, Masupirdine 100 mg, PlaceboSuven Life Sciences LimitedNeurologyPhase 3375Not sealed yet
Dec 2026Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast CancerNCT05780567 · TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen, Placebo capsules, Letrozole, Anastrozole, TamoxifenChia Tai Tianqing Pharmaceutical Group Co., Ltd.OncologyPhase 31,946Not sealed yet
Dec 2026Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDNCT04704921 · ABBV-RGX-314, ABBV-RGX-314, Ranibizumab (LUCENTIS®)AbbVieOphthalmologyPhase 2/3671Not sealed yet
Dec 2026A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022 · Selinexor (combination therapy), Selinexor (combination therapy), Selinexor (combination therapy)Karyopharm Therapeutics IncOncologyPhase 2/3501Not sealed yet
Dec 2026This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate InfluenzaNCT07371650 · TRX-100, Standard of Care (SOC)Traws Pharma, Inc.Infectious disease & vaccinesPhase 2105Not sealed yet
Dec 2026A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT06468228 · Lutikizumab, PlaceboAbbVieImmunology & inflammationPhase 31,400Not sealed yet
Dec 2026Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)NCT04639986 · Sacituzumab Govitecan-hziy, Eribulin Mesylate Injection, Capecitabine Oral ProductGilead SciencesOncologyPhase 3331Not sealed yet
Dec 2026A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutrigineNCT07010471 · 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, PlaceboPraxis Precision MedicinesNeurologyPhase 3160Not sealed yet
Dec 2026Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With PolyangiitisNCT06046222 · NS-229, PlaceboNS Pharma, Inc.Immunology & inflammationPhase 245Not sealed yet
Dec 2026A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT06707883 · TQC2731 injection, TQC2731 PlaceboShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.RespiratoryPhase 2258Not sealed yet
Dec 2026Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaNCT05948475 · Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's ChoiceTransThera Sciences (Nanjing), Inc.OncologyPhase 3200Not sealed yet
Dec 2026Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)NCT05685004 · TVI-Brain-1, Standard of Care, RadiotherapyTVAX BiomedicalOncologyPhase 2/3120Not sealed yet
Dec 2026Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderNCT07221578 · VQW-765, PlaceboVanda PharmaceuticalsPsychiatryPhase 3500Not sealed yet
Dec 1, 2026A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)NCT06685757 · Felzartamab, PlaceboBiogenKidneyPhase 3132Not sealed yet
Dec 1, 2026A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyNCT03767244 · Apalutamide, Androgen Deprivation Therapy (ADT), PlaceboJanssen Research & Development, LLCOncologyPhase 32,517Not sealed yet
Dec 1, 2026Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and AdolescentsNCT06838000 · PCV21, 20vPCVSanofi Pasteur, a Sanofi CompanyInfectious disease & vaccinesPhase 31,268Not sealed yet
Dec 1, 2026Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline DystrophyNCT06699108 · VGR-R01Shanghai Vitalgen BioPharma Co., Ltd.OphthalmologyPhase 345Not sealed yet
Dec 2, 2026A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataNCT07029711 · Ritlecitinib higher dose, Ritlecitinib lower dose, PlaceboPfizerImmunology & inflammationPhase 3208Not sealed yet
Dec 3, 2026A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's DiseaseNCT06602258 · E2814, Lecanemab, PlaceboEisai Inc.NeurologyPhase 2105Not sealed yet
Dec 3, 2026A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the BodyNCT06421636 · REGN7999, PlaceboRegeneron PharmaceuticalsHematologyPhase 219Not sealed yet
Dec 8, 2026A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.NCT07228390 · Ritlecitinib, PlaceboPfizerImmunology & inflammationPhase 2128Not sealed yet
Dec 8, 2026A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationNCT05757869 · Milvexian, Apixaban, PlaceboJanssen Research & Development, LLCCardiovascularPhase 320,284Not sealed yet
Dec 10, 2026A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.NCT07222917 · Baxdrostat/dapagliflozin, Baxdrostat/PlaceboAstraZenecaCardiovascularPhase 2222Not sealed yet
Dec 10, 2026Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentNCT06151574 · zongertinib, pembrolizumab, cisplatinBoehringer IngelheimOncologyPhase 3428Not sealed yet
Dec 11, 2026A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusNCT06778967 · GZR18, semaglutideGan & Lee Pharmaceuticals.Diabetes & obesityPhase 31,100Not sealed yet
Dec 12, 2026Efficacy and Safety of ZT006 in Overweight and Obese ParticipantsNCT07230132 · ZT006, Placebo of ZT006, ZT006Beijing QL Biopharmaceutical Co.,LtdDiabetes & obesityPhase 2184Not sealed yet
Dec 13, 2026To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic ArthritisNCT04957550 · SHR0302 tablets、Placebo, SHR0302 tablets、Placebo, PlaceboJiangsu HengRui Medicine Co., Ltd.Immunology & inflammationPhase 3418Not sealed yet
Dec 14, 2026Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)NCT06430866 · ABP 234, PembrolizumabAmgenOncologyPhase 3163Not sealed yet
Dec 14, 2026A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityNCT07184632 · NNC0662-0419, PlaceboNovo Nordisk A/SDiabetes & obesityPhase 2224Not sealed yet
Dec 14, 2026Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)NCT06122779 · BMS-986435, PlaceboBristol-Myers SquibbCardiovascularPhase 2227Not sealed yet
Dec 15, 2026Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell CarcinomaNCT05678673 · XL092, Nivolumab, Sunitinib MalateExelixisOncologyPhase 3317Not sealed yet
Dec 15, 2026A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the EyebrowsNCT07427797 · Corabotase, PlaceboIpsenOtherPhase 3309Not sealed yet
Dec 16, 2026A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisNCT05503264 · Satralizumab, PlaceboHoffmann-La RocheOncologyPhase 3122Not sealed yet
Dec 16, 2026A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerNCT06747338 · KN026, HB1801, PertuzumabShanghai JMT-Bio Inc.OncologyPhase 3520Not sealed yet
Dec 18, 2026Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide PolymorphismsNCT06062810 · Raloxifene - Usual, Raloxifene - StudyHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairOncologyPhase 2/3600Not sealed yet
Dec 18, 2026Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)NCT07246889 · AHB-137, Placebo, NA therapyAusper Biopharma Co., Ltd.Infectious disease & vaccinesPhase 3577Not sealed yet
Dec 22, 2026Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular DegenerationNCT06856577 · Ixo-vec, AfliberceptAdverum Biotechnologies, Inc.OphthalmologyPhase 3311Not sealed yet
Dec 22, 2026A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseNCT06544616 · JNJ-64042056, PlaceboJanssen Pharmaceutica N.V., BelgiumNeurologyPhase 255Not sealed yet
Dec 23, 2026A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaNCT05692180 · Benralizumab, PlaceboAstraZenecaRespiratoryPhase 394Not sealed yet
Dec 23, 2026A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCNCT05849298 · AAA617, AAA517, Piflufolastat F 18Novartis PharmaceuticalsOncologyPhase 249Not sealed yet
Dec 23, 2026FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06402331 · FPI-2265Fusion Pharmaceuticals Inc.OncologyPhase 2110Not sealed yet
Dec 25, 2026A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyNCT06769048 · Placebo-matching BI 1584862, BI 1584862Boehringer IngelheimOphthalmologyPhase 2150Not sealed yet
Dec 26, 2026Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryNCT04498117 · Oregovomab, Paclitaxel, CarboplatinCanariaBio Inc.OncologyPhase 3615Not sealed yet
Dec 26, 2026A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaNCT06212999 · PovorcitinibIncyte CorporationImmunology & inflammationPhase 3617Not sealed yet
Dec 28, 2026A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).NCT06551324 · PF-06821497, Docetaxel, EnzalutamidePfizerOncologyPhase 3600Not sealed yet
Dec 28, 2026Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSILNCT05555862 · Artesunate, PlaceboFrantz Viral Therapeutics, LLCOncologyPhase 217Not sealed yet
Dec 30, 2026Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)NCT05563844 · PM 8.4 mg/m^2, PM 11.2 mg/m^2Chengdu Zenitar Biomedical Technology Co., LtdOncologyPhase 274Not sealed yet
Dec 30, 2026A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)NCT06238843 · Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）, IBI343Innovent Biologics (Suzhou) Co. Ltd.OncologyPhase 3464Not sealed yet
Dec 30, 2026Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisNCT06799247 · Decartes-08, Placebo DrugCartesian TherapeuticsImmunology & inflammationPhase 3128Not sealed yet
Dec 30, 2026Iptacopan in Patients With ANCA Associated VasculitisNCT06388941 · Iptacopan, Placebo, RituximabNovartis PharmaceuticalsImmunology & inflammationPhase 284Not sealed yet
Dec 30, 2026ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaNCT06206733 · ASKB589, Oxaliplatin, CapecitabineAskGene Pharma, Inc.OncologyPhase 3780Not sealed yet
Dec 30, 2026Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in AdultsNCT06547151 · AMOR-1, Crystalline Calcium CarbonateAmorphical Ltd.Endocrine & bonePhase 262Not sealed yet
Dec 30, 2026SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsNCT05631262 · SKB264, DocetaxelSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.OncologyPhase 2321Not sealed yet
Dec 30, 2026Phase II Study of Hemay005 in Patients With Active Ulcerative ColitisNCT05486104 · Hemay005 tablets, Hemay005 placebo tabletsGanzhou Hemay Pharmaceutical Co., LtdImmunology & inflammationPhase 292Not sealed yet
Dec 30, 2026A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderNCT04658862 · Cetrelimab, TAR-200, CisplatinJanssen Research & Development, LLCOncologyPhase 3518Not sealed yet
Dec 30, 2026Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerNCT05909397 · Vepdegestrant (ARV-471/PF-07850327), Palbociclib, LetrozolePfizerOncologyPhase 359Not sealed yet
Dec 30, 2026A Trial of SHR-1905 in Subjects With Severe Uncontrolled AsthmaNCT05593250 · SHR-1905, placeboShanghai Hengrui Pharmaceutical Co., Ltd.RespiratoryPhase 2260Not sealed yet
Dec 30, 2026A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)NCT06782373 · Pacritinib, PlaceboSwedish Orphan BiovitrumOtherPhase 2156Not sealed yet
Dec 30, 2026SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract CancerNCT06465563 · SHR-8068, Adebrelimab, CisplatinSuzhou Suncadia Biopharmaceuticals Co., Ltd.OncologyPhase 293Not sealed yet
Dec 31, 2026A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）NCT06908876 · IBI302, IBI302, FaricimabInnovent Biologics Technology Limited (Shanghai R&D Center)OphthalmologyPhase 2150Not sealed yet
Dec 31, 2026A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)NCT06660394 · LP352, PlaceboLongboard PharmaceuticalsOtherPhase 396Not sealed yet
Dec 31, 2026A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerNCT05645692 · Atezolizumab, Tobemstomig, TiragolumabHoffmann-La RocheOncologyPhase 2204Not sealed yet
Dec 31, 2026Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 YearsNCT06281119 · Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimenSerum Institute of India Pvt. Ltd.Infectious disease & vaccinesPhase 3450Not sealed yet
Dec 31, 2026MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaNCT05464784 · MN-001, MN-001 placeboMediciNovaDiabetes & obesityPhase 240Not sealed yet
Dec 31, 2026A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate CancerNCT04691804 · Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and PrednisoneJiangsu HengRui Medicine Co., Ltd.OncologyPhase 3496Not sealed yet
Dec 31, 2026A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne VulgarisNCT07186413 · Trifarotene, Vehicle CreamGalderma R&DOtherPhase 3561Not sealed yet
Dec 31, 2026A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVTNCT05198323 · LT3001 Drug Product, PlaceboLumosa Therapeutics Co., Ltd.CardiovascularPhase 266Not sealed yet
Dec 31, 2026Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial CystitisNCT06284265 · Raphamin, PlaceboMateria Medica HoldingOtherPhase 3415Not sealed yet
Dec 31, 2026A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior UveitisNCT07136805 · VVN461 Ophthalmic Solution 1.0%, 1.0% prednisolone acetateVivaVision Biotech, IncOphthalmologyPhase 3154Not sealed yet
Dec 31, 2026EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)NCT06531824 · BI 690517, Placebo matching BI 690517, EmpagliflozinBoehringer IngelheimCardiovascularPhase 311,000Not sealed yet
Dec 31, 2026A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）NCT06884293 · IBI362, semaglutideInnovent Biologics (Suzhou) Co. Ltd.Diabetes & obesityPhase 3479Not sealed yet
Dec 31, 2026A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With PterygiumNCT05456425 · CBT-001, VehicleCloudbreak Therapeutics, LLCOtherPhase 3660Not sealed yet
Dec 31, 2026A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionNCT06903338 · Tobevibart, ElebsiranVir Biotechnology, Inc.Infectious disease & vaccinesPhase 3124Not sealed yet
Dec 31, 2026A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus ErythematosusNCT05672576 · Cenerimod, PlaceboViatris Innovation GmbHImmunology & inflammationPhase 3451Not sealed yet
Dec 31, 2026Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's DiseaseNCT05910528 · AfimkibartHoffmann-La RocheImmunology & inflammationPhase 221Not sealed yet
Dec 31, 2026Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)NCT06931405 · BLU-808, PlaceboBlueprint Medicines CorporationImmunology & inflammationPhase 2105Not sealed yet
Dec 31, 2026SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerNCT04977024 · COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1GeoVax, Inc.OncologyPhase 263Not sealed yet
Dec 31, 2026Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep ApneaNCT06776432 · Sivopixant, Placebo, AcetazolamideShionogiOtherPhase 260Not sealed yet
Dec 31, 2026A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneNCT05424835 · SHR-A1811, Pyrotinib in combination with Capecitabine., SHR-A1811Jiangsu HengRui Medicine Co., Ltd.OncologyPhase 3381Not sealed yet
Jan 2027Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresNCT07505004 · 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeksPraxis Precision MedicinesNeurologyPhase 3300Not sealed yet
Jan 2027A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin MelanomaNCT05751928 · BCD-217, anti-PD1, Excision of the primary lesionBiocadOncologyPhase 3411Not sealed yet
Jan 2027A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive TherapyNCT06384261 · Cusatuzumab, Venetoclax, AzacitidineOncoVerity, Inc.OncologyPhase 2140Not sealed yet
Jan 2027A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)NCT06109272 · Livmoniplimab, Budigalimab, DurvalumabAbbVieOncologyPhase 2/389Not sealed yet
Jan 2027A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerNCT06561607 · TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)Chia Tai Tianqing Pharmaceutical Group Co., Ltd.OncologyPhase 3542Not sealed yet
Jan 2027Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic DermatitisNCT06701331 · Placebo, UpadacitinibAbbVieImmunology & inflammationPhase 399Not sealed yet
Jan 2027A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyNCT06481891 · Sotagliflozin, PlaceboLexicon PharmaceuticalsCardiovascularPhase 3500Not sealed yet
Jan 2027A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisNCT05050136 · Volixibat, PlaceboMirum Pharmaceuticals, Inc.LiverPhase 2333Not sealed yet
Jan 2027A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)NCT05540860 · Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3Edgewise Therapeutics, Inc.Rare genetic diseasePhase 276Not sealed yet
Jan 2027A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesNCT05329766 · Domvanalimab, Quemliclustat, ZimberelimabArcus Biosciences, Inc.OtherPhase 2332Not sealed yet
Jan 2027Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49NCT07284654 · 31 valent pneumococcal conjugate vaccine, PCV20, PCV21Vaxcyte, Inc.Infectious disease & vaccinesPhase 34,049Not sealed yet
Jan 2027Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisNCT06029972 · Tilpisertib Fosmecarbil, PlaceboGilead SciencesImmunology & inflammationPhase 2176Not sealed yet
Jan 2027Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes MellitusNCT07205900 · HM15275, Placebo of HM15275Hanmi Pharmaceutical Company LimitedDiabetes & obesityPhase 2267Not sealed yet
Jan 2027A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With GlioblastomaNCT04485949 · IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation TherapyImvaxOncologyPhase 299Not sealed yet
Jan 1, 2027Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSNCT04957485 · Tecovirimat, Smallpox and Mpox Vaccine, PlaceboSIGA TechnologiesOtherPhase 2100Not sealed yet
Jan 4, 2027A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHNCT07000136 · AZD0780, PlaceboAstraZenecaCardiovascularPhase 3473Not sealed yet
Jan 4, 2027A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)NCT06356311 · Sacituzumab tirumotecan, Trifluridine-Tipiracil, IrinotecanMerck Sharp & Dohme LLCOncologyPhase 3450Not sealed yet
Jan 6, 2027Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)NCT05925803 · Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label)AstraZenecaImmunology & inflammationPhase 3314Not sealed yet
Jan 8, 2027Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationNCT06495918 · OTX-TKI, Aflibercept, AfliberceptOcular Therapeutix, Inc.OphthalmologyPhase 3825Not sealed yet
Jan 8, 2027A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis BronchiectasisNCT06981091 · XH-S004 20 mg, XH-S004 40 mg, PlaceboShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.RespiratoryPhase 2234Not sealed yet
Jan 11, 2027A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventNCT07000123 · AZD0780, PlaceboAstraZenecaCardiovascularPhase 33,103Not sealed yet
Jan 12, 2027Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)NCT05609968 · Sacituzumab Govitecan, PembrolizumabMerck Sharp & Dohme LLCOncologyPhase 3614Not sealed yet
Jan 13, 2027Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet TherapyNCT05952206 · Angiolite: Sirolimus-eluting stent, Xience: Everolimus-eluting stent, 1-month DAPTiVascular S.L.U.CardiovascularPhase 32,312Not sealed yet
Jan 15, 2027IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaNCT05987332 · IDE196, Crizotinib, PembrolizumabIDEAYA BiosciencesOncologyPhase 2/3420Not sealed yet
Jan 18, 2027Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.NCT05035212 · RSVpreF, PlaceboPfizerInfectious disease & vaccinesPhase 338,861Not sealed yet
Jan 21, 2027Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 · Maridebart cafraglutide, PlaceboAmgenDiabetes & obesityPhase 31,105Not sealed yet
Jan 21, 2027Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · Maridebart Cafraglutide, PlaceboAmgenDiabetes & obesityPhase 33,853Not sealed yet
Jan 25, 2027A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNCT07076199 · Insulin icodec, Insulin glargine, Insulin aspartNovo Nordisk A/SDiabetes & obesityPhase 3877Not sealed yet
Jan 25, 2027PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerNCT06616532 · PM8002, Paclitaxel, TopotecanBiotheus Inc.OncologyPhase 3404Not sealed yet
Jan 28, 2027Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.NCT05038735 · Alpelisib, Fulvestrant, Alpelisib-matching placeboNovartis PharmaceuticalsOncologyPhase 3210Not sealed yet
Jan 28, 2027A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsNCT07496450 · mRNA-1018-H5, PlaceboModernaTX, Inc.Infectious disease & vaccinesPhase 34,050Not sealed yet
Jan 29, 2027Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerNCT04544189 · Alpelisib, Fulvestrant, PlaceboNovartis PharmaceuticalsOncologyPhase 269Not sealed yet
Jan 29, 2027ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackNCT06118281 · Ziltivekimab, PlaceboNovo Nordisk A/SCardiovascularPhase 310,000Not sealed yet
Jan 29, 2027Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2NCT05911295 · disitamab vedotin, pembrolizumab, gemcitabineSeagen, a wholly owned subsidiary of PfizerOncologyPhase 3412Not sealed yet
Jan 29, 2027A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsNCT06857955 · Saline, QCZ484Novartis PharmaceuticalsCardiovascularPhase 2396Not sealed yet
Jan 30, 2027A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisNCT06589986 · Afimkibart, PlaceboHoffmann-La RocheImmunology & inflammationPhase 3400Not sealed yet
Jan 31, 2027Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLNCT03836261 · Acalabrutinib, Venetoclax, ChemoimmunotherapyAcerta Pharma BVOncologyPhase 3984Not sealed yet
Jan 31, 2027Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)NCT04241185 · Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes)Merck Sharp & Dohme LLCOncologyPhase 3520Not sealed yet
Feb 2027A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionNCT06365853 · Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye dropsAbbVieOncologyPhase 2108Not sealed yet
Feb 2027A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following RadiotherapyNCT06413706 · Abemaciclib, TemozolomideEli Lilly and CompanyOncologyPhase 245Not sealed yet
Feb 2027A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus InfectionNCT07245953 · HT-101, HT-102, HT-101 placeboSuzhou HepaThera Biotech Co., Ltd.Infectious disease & vaccinesPhase 260Not sealed yet
Feb 2027A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung CancerNCT06939595 · CT-P51, EU-approved KeytrudaCelltrionOncologyPhase 3225Not sealed yet
Feb 2027A Phase IIb Study of 610 in Participants With Severe Eosinophilic AsthmaNCT06680947 · 610, 610, PlaceboSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.RespiratoryPhase 2225Not sealed yet
Feb 2027A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV VaccineNCT06899802 · MVA-BN-WEV, PlaceboBavarian NordicInfectious disease & vaccinesPhase 2411Not sealed yet
Feb 2027Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · Sacituzumab Govitecan-hziy, Pembrolizumab, PaclitaxelGilead SciencesOncologyPhase 3443Not sealed yet
Feb 2027A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related CataractNCT07395986 · 0.4% ZOC2017217, ControlOcusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.OtherPhase 28Not sealed yet
Feb 2, 2027An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.NCT05217628 · Basimglurant, PlaceboNoema Pharma AGPainPhase 2/3166Not sealed yet
Feb 2, 2027Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaNCT04417621 · LXH254, LTT462, TrametinibNovartis PharmaceuticalsOncologyPhase 2134Not sealed yet
Feb 3, 2027Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate VaccineNCT07743008 · Haemophilus influenzae serotype a vaccine candidate, Saline (as a placebo)InventVacc Biologicals Inc.Diabetes & obesityPhase 247Not sealed yet
Feb 4, 2027A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)NCT04657289 · Ranibizumab, Port Delivery System with RanibizumabHoffmann-La RocheOphthalmologyPhase 3451Not sealed yet
Feb 4, 2027Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugNCT06641076 · Sonelokimab, PlaceboMoonLake Immunotherapeutics AGImmunology & inflammationPhase 3960Not sealed yet
Feb 5, 2027A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)NCT06946797 · Nivolumab, Ipilimumab, CarboplatinBristol-Myers SquibbOncologyPhase 276Not sealed yet
Feb 9, 2027Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric CancerNCT05771584 · AST-301, rhuGM-CSFAston Sci. Inc.OncologyPhase 224Not sealed yet
Feb 10, 2027A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisNCT06260163 · Guselkumab Subcutaneous, Guselkumab IntravenousJanssen Research & Development, LLCImmunology & inflammationPhase 3112Not sealed yet
Feb 12, 2027A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaNCT06388200 · Sub-Retinal Administration of OCU400-301OcugenOphthalmologyPhase 3140Not sealed yet
Feb 13, 2027A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.NCT04224493 · Tazemetostat, Tazemetostat, Placebo oral tabletEpizyme, Inc.OncologyPhase 3599Not sealed yet
Feb 15, 2027A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)NCT07017777 · PCV13i, Prevnar 13CanSino Biologics Inc.Infectious disease & vaccinesPhase 3600Not sealed yet
Feb 15, 2027A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisNCT06592794 · mRNA-1403, PlaceboModernaTX, Inc.OtherPhase 337,864Not sealed yet
Feb 15, 2027A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLNCT02972840 · Acalabrutinib, Bendamustine, RituximabAcerta Pharma BVOncologyPhase 3635Not sealed yet
Feb 16, 2027A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)NCT06140836 · Repotrectinib, CrizotinibBristol-Myers SquibbOncologyPhase 3190Not sealed yet
Feb 17, 2027An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal PolypsNCT07424144 · Itepekimab (SAR440340), PlaceboSanofiRespiratoryPhase 359Not sealed yet
Feb 18, 2027Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)NCT06087835 · Zibotentan/Dapagliflozin, DapagliflozinAstraZenecaKidneyPhase 31,835Not sealed yet
Feb 22, 2027A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)NCT04529772 · acalabrutinib, placebo, PrednisoneAcerta Pharma BVOncologyPhase 3611Not sealed yet
Feb 23, 2027Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisNCT05138133 · Anifrolumab, PlaceboAstraZenecaKidneyPhase 3363Not sealed yet
Feb 26, 2027Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA MutationNCT04208178 · Alpelisib, Alpelisib matching Placebo, TrastuzumabNovartis PharmaceuticalsOncologyPhase 319Not sealed yet
Feb 27, 2027A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)NCT07073417 · XW003 injection, semaglutide injectionHangzhou Sciwind Biosciences Co., Ltd.Diabetes & obesityPhase 2163Not sealed yet
Feb 28, 2027ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeNCT04587830 · ADI-PEG 20, Temozolomide, PlaceboPolaris GroupOncologyPhase 2100Not sealed yet
Feb 28, 2027A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMDNCT05972473 · Aflibercept Ophthalmic, IBI302Innovent Biologics (Suzhou) Co. Ltd.OphthalmologyPhase 3600Not sealed yet
Feb 28, 2027A Study Evaluating BFB759 in Moderate to Severe Atopic DermatitisNCT07105488 · BFB759, PlaceboBluefin Biomedicine, Inc.Immunology & inflammationPhase 2225Not sealed yet
Mar 2027Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene TherapyNCT06100887 · Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3Edgewise Therapeutics, Inc.Rare genetic diseasePhase 243Not sealed yet
Mar 2027A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgeNCT07365826 · 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), PlaceboVaxcyte, Inc.Infectious disease & vaccinesPhase 31,390Not sealed yet
Mar 2027RBD5044 in Chinese Participants With HypertriglyceridemiaNCT07587788 · RBD5044, PlaceboRibotek Biopharmaceuticals (Shandong) Co., LtdDiabetes & obesityPhase 240Not sealed yet
Mar 2027A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentNCT06668805 · Vosoritide InjectionBioMarin PharmaceuticalEndocrine & bonePhase 230Not sealed yet
Mar 2027A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)NCT04951219 · ResmetiromMadrigal Pharmaceuticals, Inc.LiverPhase 3810Not sealed yet
Mar 2027Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus ErythematosusNCT05843643 · Upadacitinib, PlaceboAbbVieImmunology & inflammationPhase 31,014Not sealed yet
Mar 2027Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsNCT07502495 · icovamenib 100mg, PlaceboBiomea Fusion Inc.Diabetes & obesityPhase 264Not sealed yet
Mar 2027A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.NCT06063967 · Risankizumab SC, Placebo for risankizumabAbbVieImmunology & inflammationPhase 3289Not sealed yet
Mar 2027Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)NCT05186974 · Sacituzumab Govitecan-hziy (SG), Pembrolizumab, CarboplatinGilead SciencesOncologyPhase 2193Not sealed yet
Mar 2027A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerNCT05141721 · GRT-C901, GRT-R902, AtezolizumabSeattle Project CorporationOncologyPhase 2/3700Not sealed yet
Mar 2027Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01NCT06727565 · Domvanalimab, Zimberelimab, PaclitaxelGilead SciencesOncologyPhase 239Not sealed yet
Mar 2027Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)NCT06632951 · Livmoniplimab, Budigalimab, DocetaxelAbbVieOncologyPhase 2150Not sealed yet
Mar 2027Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationNCT07425392 · 31-valent pneumococcal conjugate vaccine, PCV20Vaxcyte, Inc.Infectious disease & vaccinesPhase 3752Not sealed yet
Mar 2027A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationNCT04002297 · zanubrutinib, bendamustine, rituximabBeOne MedicinesOncologyPhase 3510Not sealed yet
Mar 2027Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)NCT06602193 · BIIB122 225 mg, BIIB122-Matching PlaceboDenali Therapeutics Inc.NeurologyPhase 250Not sealed yet
Mar 2027A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaNCT06929624 · SHR-A1912 Injection, Rituximab Injection, Gemcitabine Hydrochloride for InjectionSuzhou Suncadia Biopharmaceuticals Co., Ltd.OncologyPhase 3282Not sealed yet
Mar 2027A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With ObesityNCT07285902 · HRS9531 injection, Semaglutide InjectionFujian Shengdi Pharmaceutical Co., Ltd.Diabetes & obesityPhase 3572Not sealed yet
Mar 2027A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)NCT06963710 · ALG-000184, TDFAligos TherapeuticsInfectious disease & vaccinesPhase 2200Not sealed yet
Mar 1, 2027A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMENCT06957080 · EYE103, RanibizumabEyeBiotech Ltd.OphthalmologyPhase 2/31,054Not sealed yet
Mar 1, 2027A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667 · CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Novo Nordisk A/SDiabetes & obesityPhase 3609Not sealed yet
Mar 1, 2027An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASNCT02531516 · Apalutamide, Bicalutamide, Bicalutamide PlaceboAragon Pharmaceuticals, Inc.OncologyPhase 31,503Not sealed yet
Mar 5, 2027A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyNCT06321302 · BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US onlyBoehringer IngelheimOphthalmologyPhase 2190Not sealed yet
Mar 6, 2027A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.NCT05683457 · mRNA-1647, PlaceboModernaTX, Inc.Infectious disease & vaccinesPhase 284Not sealed yet
Mar 9, 2027A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque PsoriasisNCT06506916 · bimekizumabUCB Biopharma SRLImmunology & inflammationPhase 389Not sealed yet
Mar 10, 2027Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy AdolescentsNCT05087056 · MenABCWY vaccine, PlaceboGlaxoSmithKlineOtherPhase 2305Not sealed yet
Mar 11, 2027A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerNCT03873402 · Nivolumab, Ipilimumab, Ipilimumab placeboBristol-Myers SquibbOncologyPhase 3437Not sealed yet
Mar 11, 2027A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard TreatmentNCT07036523 · BI 765423, PlaceboBoehringer IngelheimRespiratoryPhase 281Not sealed yet
Mar 13, 2027A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sNCT06928142 · Sibeprenlimab, PlaceboOtsuka Pharmaceutical Development & Commercialization, Inc.Immunology & inflammationPhase 283Not sealed yet
Mar 14, 2027A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye DiseaseNCT07211776 · ZL-1109 (VRDN-003), PlaceboZai Lab (Shanghai) Co., Ltd.OphthalmologyPhase 3108Not sealed yet
Mar 17, 2027A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT06789289 · TQC2938 injection, TQC2938 injection PlaceboChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.RespiratoryPhase 2256Not sealed yet
Mar 18, 2027Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseNCT06268886 · BMS-986446, PlaceboBristol-Myers SquibbNeurologyPhase 2310Not sealed yet
Mar 22, 2027Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)NCT04976634 · Pembrolizumab, Belzutifan, LenvatinibMerck Sharp & Dohme LLCOncologyPhase 2730Not sealed yet
Mar 25, 2027A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's DiseaseNCT05347095 · Guselkumab, PlaceboJanssen-Cilag Ltd.Immunology & inflammationPhase 3288Not sealed yet
Mar 25, 202753-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the KneeNCT06865079 · TPX-100 200mg, Once weekly for 4 weeks, PBSOrthoTrophix, IncImmunology & inflammationPhase 2270Not sealed yet
Mar 26, 2027Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)NCT05639114 · Ianalumab, PlaceboNovartis PharmaceuticalsImmunology & inflammationPhase 3436Not sealed yet
Mar 28, 2027Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)NCT06524947 · quadrivalent recombinant norovirus vaccine (Pichia pastoris), quadrivalent recombinant norovirus vaccine (Pichia pastoris) placeboAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Infectious disease & vaccinesPhase 36,600Not sealed yet
Mar 31, 2027Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This MedicineNCT05846230 · BI 1291583, Placebo matching BI 1291583Boehringer IngelheimRespiratoryPhase 2268Not sealed yet
Mar 31, 2027A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoNCT06163326 · Ritlecitinib, Ritlecitinib 100 mg, PlaceboPfizerImmunology & inflammationPhase 3394Not sealed yet
Mar 31, 2027Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar DegenerationNCT07040137 · KPS-0373, PlaceboKissei Pharmaceutical Co., Ltd.OtherPhase 3142Not sealed yet
Mar 31, 2027A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous NephropathyNCT06642909 · Zuberitamab 600mg, Zuberitamab 1000mg, cyclosporineBioRay Pharmaceutical Co., Ltd.KidneyPhase 2135Not sealed yet
Mar 31, 2027Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.NCT05270044 · Encorafenib and Binimetinib, Placebo to match Encorafenib ; Placebo to match BinimetinibPierre Fabre MedicamentOncologyPhase 3815Not sealed yet
Mar 31, 2027A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyNCT04873362 · Atezolizumab, Trastuzumab Emtansine, PlaceboHoffmann-La RocheOncologyPhase 31,188Not sealed yet
Mar 31, 2027A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus ErythematosusNCT05648500 · Cenerimod, PlaceboViatris Innovation GmbHImmunology & inflammationPhase 3470Not sealed yet
Apr 2027Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNCT06334133 · Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, PlacebovTv TherapeuticsDiabetes & obesityPhase 3150Not sealed yet
Apr 2027KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisNCT06384976 · KYV-101, Standard lymphodepletion regimen, Anti-CD20 mABKyverna TherapeuticsNeurologyPhase 2120Not sealed yet
Apr 2027Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint InfectionNCT06621251 · TRL1068 (calpurbatug), a human monoclonal antibody, DAIRTrellis Bioscience LLCInfectious disease & vaccinesPhase 260Not sealed yet
Apr 2027Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)NCT06489028 · allo-APZ2-CVU, PlaceboRHEACELL GmbH & Co. KGOtherPhase 3250Not sealed yet
Apr 2027A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsNCT07185776 · HRS-5632 Injection, HRS-5632 Injection PlaceboFujian Shengdi Pharmaceutical Co., Ltd.CardiovascularPhase 2203Not sealed yet
Apr 2027Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSNCT04057898 · MN-166, placeboMediciNovaNeurologyPhase 2/3234Not sealed yet
Apr 2027Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerNCT05445778 · Mirvetuximab soravtansine plus Bevacizumab, BevacizumabAbbVieOncologyPhase 3520Not sealed yet
Apr 1, 2027Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With MyopiaNCT07790640 · CTO0308, Vehicle (Placebo solution)Taejoon Pharmaceutical Co., Ltd.OphthalmologyPhase 3351Not sealed yet
Apr 5, 2027A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantNCT03319667 · Isatuximab SAR650984, Bortezomib, LenalidomideSanofiOncologyPhase 3475Not sealed yet
Apr 10, 2027A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaNCT05196035 · Finerenone (Kerendia, BAY94-8862), PlaceboBayerKidneyPhase 3219Not sealed yet
Apr 12, 2027Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)NCT05624749 · ianalumab, placeboNovartis PharmaceuticalsImmunology & inflammationPhase 3288Not sealed yet
Apr 14, 2027A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)NCT06579755 · TDV, PlaceboTakedaInfectious disease & vaccinesPhase 3800Not sealed yet
Apr 18, 2027A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement InhibitorsNCT04432584 · Crovalimab, EculizumabHoffmann-La RocheHematologyPhase 3190Not sealed yet
Apr 19, 2027Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)NCT06700343 · Ocrelizumab (US), Ocrelizumab (EU), ABP 692AmgenNeurologyPhase 3152Not sealed yet
Apr 22, 2027Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)NCT06497504 · Bepirovirsen, PlaceboGlaxoSmithKlineInfectious disease & vaccinesPhase 2153Not sealed yet
Apr 25, 2027A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic DermatitisNCT06526182 · Lebrikizumab, PlaceboAlmirall, S.A.Immunology & inflammationPhase 3520Not sealed yet
Apr 26, 2027A Study of DII235 in Adults With Elevated Lipoprotein(a)NCT07235046 · DII235, SalineNovartis PharmaceuticalsOtherPhase 2234Not sealed yet
Apr 27, 2027Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity DiseaseNCT06987695 · Maridebart cafraglutide, PlaceboAmgenDiabetes & obesityPhase 3279Not sealed yet
Apr 28, 2027Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)NCT06111586 · Frexalimab, Placebo, InsulinSanofiDiabetes & obesityPhase 2197Not sealed yet
Apr 29, 2027Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® MoleculeNCT06812988 · Brivekimig, PlaceboSanofiDiabetes & obesityPhase 284Not sealed yet
Apr 30, 2027Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot UlcersNCT06189638 · Antimicrobial Peptide PL-5 Topical Spray and PlaceboJiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.Diabetes & obesityPhase 290Not sealed yet
Apr 30, 2027A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.NCT06517758 · Iptacopan, Matching PlaceboNovartis PharmaceuticalsImmunology & inflammationPhase 3146Not sealed yet
Apr 30, 2027Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)NCT07741526 · NPI-001, PlaceboArctic TherapeuticsNeurologyPhase 233Not sealed yet
Apr 30, 2027A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic EsophagitisNCT06598462 · Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High DoseUniquity One (UNI)OtherPhase 2184Not sealed yet
Apr 30, 2027Tigulixostat (IBI128) vs Febuxostat in GoutNCT07414394 · Febuxostat, TigulixostatInnovent Biologics Technology Limited (Shanghai R&D Center)Immunology & inflammationPhase 3600Not sealed yet
May 2027A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 InfectionNCT06672055 · VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3VaxartInfectious disease & vaccinesPhase 25,485Not sealed yet
May 2027Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173 · Domvanalimab, Zimberelimab, CarboplatinArcus Biosciences, Inc.OncologyPhase 2169Not sealed yet
May 2027A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic DermatitisNCT06718101 · Lutikizumab, PlaceboAbbVieImmunology & inflammationPhase 283Not sealed yet
May 2027A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral AdrenoleukodystrophyNCT05819866 · Leriglitazone, PlaceboMinoryx Therapeutics, S.L.OtherPhase 340Not sealed yet
May 2027A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06670196 · SKB264, OsimertinibSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.OncologyPhase 3420Not sealed yet
May 2027Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's DiseaseNCT06873334 · SKY-0515, SKY-0515 PlaceboSkyhawk Therapeutics, Inc.NeurologyPhase 2/3120Not sealed yet
May 2027Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesNCT07458269 · Ribupatide, PlaceboKaileraDiabetes & obesityPhase 2264Not sealed yet
May 2027HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies StudyNCT07215468 · TMB-365, TMB-380, Baseline ARTTaiMed Biologics Inc.Infectious disease & vaccinesPhase 288Not sealed yet
May 2027A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.NCT06588686 · Buloxibutid, PlaceboVicore Pharma ABRespiratoryPhase 2378Not sealed yet
May 2027Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)NCT06843239 · Tibulizumab, PlaceboZura Bio IncImmunology & inflammationPhase 280Not sealed yet
May 1, 2027Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDSNCT05938036 · ALT-100 mAb, ALT-100 (Placebo)Aqualung Therapeutics Corp.OtherPhase 215Not sealed yet
May 1, 2027A Study to Learn About How a New Pneumococcal Vaccine Works in InfantsNCT06524414 · PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)PfizerInfectious disease & vaccinesPhase 2605Not sealed yet
May 4, 2027Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)NCT04379596 · Fluorouracil (5-FU), Capecitabine, DurvalumabAstraZenecaOncologyPhase 2452Not sealed yet
May 4, 2027Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaNCT05972551 · Romosozumab, BisphosphonateAmgenOtherPhase 3111Not sealed yet
May 5, 2027Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)NCT06428396 · Belzutifan, Fulvestrant, EverolimusMerck Sharp & Dohme LLCOncologyPhase 2120Not sealed yet
May 5, 2027Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)NCT04380636 · Pembrolizumab, Olaparib, Placebo for olaparibMerck Sharp & Dohme LLCOncologyPhase 3870Not sealed yet
May 6, 2027Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473 · Frexalimab, Teriflunomide, Placebo infusionSanofiNeurologyPhase 31,655Not sealed yet
May 6, 2027A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)NCT05063162 · Rozanolixizumab, PlaceboUCB Biopharma SRLDiabetes & obesityPhase 3113Not sealed yet
May 10, 2027Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseNCT05030428 · Inclisiran sodium 300 mg, PlaceboNovartis PharmaceuticalsCardiovascularPhase 317,004Not sealed yet
May 10, 2027Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)NCT06074588 · Sacituzumab tirumotecan, Docetaxel, PemetrexedMerck Sharp & Dohme LLCOncologyPhase 3556Not sealed yet
May 11, 2027Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642 · Cagrilintide, PlaceboNovo Nordisk A/SDiabetes & obesityPhase 3300Not sealed yet
May 12, 2027Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759 · Cagrilintide, Placebo (matched to Cagrilintide)Novo Nordisk A/SDiabetes & obesityPhase 3330Not sealed yet
May 17, 2027A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)NCT06799000 · Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1Novartis PharmaceuticalsImmunology & inflammationPhase 3588Not sealed yet
May 17, 2027Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06736041 · PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccineSanofi Pasteur, a Sanofi CompanyInfectious disease & vaccinesPhase 31,714Not sealed yet
May 17, 2027A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic DermatitisNCT07277660 · Galvokimig, PlaceboUCB Biopharma SRLImmunology & inflammationPhase 2165Not sealed yet
May 17, 2027Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic DermatitisNCT07220577 · GIA632, PlaceboNovartis PharmaceuticalsImmunology & inflammationPhase 234Not sealed yet
May 19, 2027A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)NCT05624554 · Nemtabrutinib, Fludarabine, CyclophosphamideMerck Sharp & Dohme LLCOncologyPhase 3300Not sealed yet
May 20, 2027A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisNCT03958877 · BIIB017 (peginterferon beta-1a), Interferon beta type 1aBiogenNeurologyPhase 3152Not sealed yet
May 20, 2027A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)NCT06465329 · Cemiplimab, Platinum-based chemotherapy, REGN7075Regeneron PharmaceuticalsOncologyPhase 2120Not sealed yet
May 27, 2027REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)NCT05973773 · TAS6417Taiho Oncology, Inc.OncologyPhase 3285Not sealed yet
May 27, 2027Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)NCT05173987 · pembrolizumab, carboplatin, paclitaxelMerck Sharp & Dohme LLCOncologyPhase 3280Not sealed yet
May 29, 2027A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)NCT07230119 · Zovaglutide dose 1, Zovaglutide dose 2, PlaceboBeijing QL Biopharmaceutical Co.,LtdDiabetes & obesityPhase 3755Not sealed yet
May 31, 2027Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibNCT06120140 · Amivantamab IV, Amivantamab SC, LazertinibJanssen Research & Development, LLCOncologyPhase 2305Not sealed yet
May 31, 2027A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseNCT05531656 · CT1812, PlaceboCognition TherapeuticsNeurologyPhase 2540Not sealed yet
May 31, 2027A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)NCT05881408 · delandistrogene moxeparvovec, placeboSarepta Therapeutics, Inc.Rare genetic diseasePhase 3148Not sealed yet
May 31, 2027A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)NCT06537414 · Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, BepirovirsenGlaxoSmithKlineInfectious disease & vaccinesPhase 2283Not sealed yet
Jun 2027A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic DermatitisNCT07217015 · KT-621, PlaceboKymera Therapeutics, Inc.Immunology & inflammationPhase 2200Not sealed yet
Jun 2027A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast CancerNCT03980054 · Pyrotinib, PlaceboJiangsu HengRui Medicine Co., Ltd.OncologyPhase 32,135Not sealed yet
Jun 2027A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary FibrosisNCT06329401 · AP01, PlaceboAvalyn Pharma Inc.Immunology & inflammationPhase 2375Not sealed yet
Jun 2027A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late XerostomiaNCT05926765 · AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, PlaceboMeiraGTx, LLCOncologyPhase 2290Not sealed yet
Jun 2027Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07290569 · ORKA-001, PlaceboOruka Therapeutics, Inc.Immunology & inflammationPhase 2160Not sealed yet
Jun 20274D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNCT06864988 · 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)4D Molecular TherapeuticsOphthalmologyPhase 3480Not sealed yet
Jun 2027Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute PancreatitisNCT07308392 · HRS-7249 injection set, SHR-1918 injection set, HRS-7249 injection placebo setFujian Shengdi Pharmaceutical Co., Ltd.Diabetes & obesityPhase 2119Not sealed yet
Jun 2027Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)NCT06726265 · eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexedImmutep S.A.S.OncologyPhase 3756Not sealed yet
Jun 2027AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial DysfunctionNCT07368959 · Combination Product: AURN001 + Y-27632, PlaceboAurion BiotechOphthalmologyPhase 3130Not sealed yet
Jun 2027DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)NCT05566795 · Tovorafenib, Chemotherapeutic AgentDay One Biopharmaceuticals, Inc.OncologyPhase 3418Not sealed yet
Jun 2027A Study of SHR-1819 in Patients With Moderate-to-severe Atopic DermatitisNCT07321951 · SHR-1819 Injection, SHR-1819 Injection Blank PreparationGuangdong Hengrui Pharmaceutical Co., LtdImmunology & inflammationPhase 2201Not sealed yet
Jun 2027Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)NCT07146022 · VDPHL01 QD, Placebo, VDPHL01 BIDVeradermics, Inc.Immunology & inflammationPhase 3552Not sealed yet
Jun 2027Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With ChemotherapyNCT06449209 · BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), EtoposideBioNTech SEOncologyPhase 2110Not sealed yet
Jun 2027A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)NCT05578976 · Epcoritamab, Cyclophosphamide, RituximabGenmabOncologyPhase 3900Not sealed yet
Jun 2027To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring HemodialysisNCT05908084 · Acellular Tissue Engineered Vessel (ATEV), AVFHumacyte, Inc.KidneyPhase 3121Not sealed yet
Jun 2027Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSENCT04919226 · 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid SolutionITM Solucin GmbHOncologyPhase 3259Not sealed yet
Jun 1, 2027A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseNCT06388564 · Axatilimab, Ruxolitinib, CorticosteroidsIncyte CorporationOtherPhase 2130Not sealed yet
Jun 3, 2027A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis SuppurativaNCT06840392 · Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1Novartis PharmaceuticalsImmunology & inflammationPhase 3565Not sealed yet
Jun 14, 2027A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityNCT07639021 · NNC0662-0419, Semaglutide, NNC0662-0419 PlaceboNovo Nordisk A/SDiabetes & obesityPhase 2233Not sealed yet
Jun 21, 2027Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319 · Lunsekimig, Short-Acting Beta Agonists (SABA), PlaceboSanofiRespiratoryPhase 2556Not sealed yet
Jun 23, 2027(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisNCT03731260 · Avapritinib, PlaceboBlueprint Medicines CorporationOtherPhase 2251Not sealed yet
Jun 25, 2027Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.NCT06473779 · Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®)AstraZenecaRespiratoryPhase 3326Not sealed yet
Jun 30, 2027A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)NCT07159763 · MK-1406, PlaceboCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Infectious disease & vaccinesPhase 310,000Not sealed yet
Jun 30, 2027Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCNCT04550260 · Durvalumab, Placebo, cisplatin + fluorouracilAstraZenecaOncologyPhase 3640Not sealed yet
Jun 30, 2027A Phase 2 Study of YA-101 in Patients With Multiple System AtrophyNCT06848231 · YA-101, PlaceboDasher Neuroscience Inc.OtherPhase 275Not sealed yet
Jun 30, 2027Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical TrialNCT04003857 · PNEUMOSTEM®, normal salineMedipost Co Ltd.RespiratoryPhase 260Not sealed yet
Jun 30, 2027Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic AtrophyNCT05949593 · Tinlarebant, PlaceboBelite Bio, IncOtherPhase 3429Not sealed yet
Jun 30, 2027A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBMNCT03862430 · NanO2TM, Placebo Saline InfusionNuvOx LLCOncologyPhase 287Not sealed yet
Jun 30, 2027A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)NCT05562947 · PDS With Ranibizumab (100 mg/mL), Ranibizumab (10 mg/mL)Hoffmann-La RocheOphthalmologyPhase 368Not sealed yet
Jun 30, 2027A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)NCT03178552 · Alectinib, Atezolizumab, PemetrexedHoffmann-La RocheOncologyPhase 2/31,000Not sealed yet
Jun 30, 2027Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial CarcinomaNCT03967977 · Tislelizumab, Placebo, CisplatinBeiGeneOncologyPhase 3420Not sealed yet
Jul 2027Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back PainNCT06325566 · Rexlemestrocel-L + HA mixture, SalineMesoblast, Ltd.PainPhase 3300Not sealed yet
Jul 2027A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 · Retatrutide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3250Not sealed yet
Jul 2027PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCNCT06419621 · PM8002, Nab-Paclitaxel, PlaceboBiotheus Inc.OncologyPhase 3392Not sealed yet
Jul 2027A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromeNCT06684847 · Efgartigimod PH20 SC, Placebo PH20 SCargenxImmunology & inflammationPhase 3631Not sealed yet
Jul 2027A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.NCT06917404 · Pentosan Polysulfate Sodium twice weekly, PlaceboParadigm Biopharmaceuticals Ltd.Immunology & inflammationPhase 3466Not sealed yet
Jul 2027Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe AsthmaNCT07120503 · WIN378, PlaceboWindward BioRespiratoryPhase 2136Not sealed yet
Jul 2027Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe PainNCT04333576 · Elagolix, Placebo, Combined Oral ContraceptiveAbbViePainPhase 3800Not sealed yet
Jul 2027Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic SyndromeNCT04401748 · Venetoclax, Azacitidine, PlaceboAbbVieOncologyPhase 3531Not sealed yet
Jul 1, 2027VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 · VK2735Viking Therapeutics, Inc.Diabetes & obesityPhase 31,100Not sealed yet
Jul 1, 2027VK2735 for Weight Management Phase 3NCT07104500 · VK2735Viking Therapeutics, Inc.OtherPhase 34,500Not sealed yet
Jul 1, 2027RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck CancerNCT05966194 · RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2EpicentRx, Inc.OncologyPhase 2216Not sealed yet
Jul 5, 2027Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabNCT06211036 · Tarlatamab, DurvalumabAmgenOncologyPhase 3563Not sealed yet
Jul 7, 2027Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityNCT07497880 · KAI-7535, PlaceboKaileraDiabetes & obesityPhase 2306Not sealed yet
Jul 15, 2027A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT05057494 · Acalabrutinib, Venetoclax, ObinutuzumabAstraZenecaOncologyPhase 3607Not sealed yet
Jul 16, 2027A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07047118 · JSB462, AAA617Novartis PharmaceuticalsOncologyPhase 2138Not sealed yet
Jul 16, 2027A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaNCT05664737 · Luspatercept, PlaceboBristol-Myers SquibbHematologyPhase 2189Not sealed yet
Jul 20, 2027A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DMENCT04108156 · PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchangeHoffmann-La RocheOphthalmologyPhase 3672Not sealed yet
Jul 22, 2027A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)NCT07044297 · MK-8527, FTC/TDF, Placebo to MK-8527Merck Sharp & Dohme LLCInfectious disease & vaccinesPhase 34,390Not sealed yet
Jul 30, 2027A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2NCT06072183 · Ritlecitinib, Ritlecitinib, PlaceboPfizerImmunology & inflammationPhase 31,571Not sealed yet
Jul 30, 2027A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese MalesNCT06465914 · 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), PlaceboShanghai Bovax Biotechnology Co., Ltd.OncologyPhase 39,000Not sealed yet
Jul 30, 2027A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesNCT05794906 · Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADTBayerOncologyPhase 3985Not sealed yet
Jul 30, 2027A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentNCT05455320 · Talquetamab, Daratumumab, PomalidomideJanssen Research & Development, LLCOncologyPhase 3864Not sealed yet
Jul 30, 2027Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)NCT06635824 · Acasunlimab, Pembrolizumab, DocetaxelGenmabOncologyPhase 3191Not sealed yet
Jul 30, 2027Volrustomig Priming Regimens Exploratory Phase II Platform StudyNCT06448754 · Volrustomig, Carboplatin, PemetrexedAstraZenecaOncologyPhase 2194Not sealed yet
Jul 30, 2027A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)NCT06079879 · Bomedemstat, Anagrelide, BusulfanMerck Sharp & Dohme LLCCardiovascularPhase 3340Not sealed yet
Aug 2027A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792 · Orforglipron, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 31,400Not sealed yet
Aug 2027A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459 · Orforglipron, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3800Not sealed yet
Aug 2027A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAODNCT05933200 · Triheptanoin, MCT OilUltragenyx Pharmaceutical IncOtherPhase 369Not sealed yet
Aug 2027Long-Term PEA Safety StudyNCT06717867 · Palmitoylethanolamide (PEA), PlaceboRDC Clinical Pty LtdOtherPhase 2200Not sealed yet
Aug 2027ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)NCT06373731 · Elamipretide, PlaceboStealth BioTherapeutics Inc.OphthalmologyPhase 3313Not sealed yet
Aug 2027A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472 · Orforglipron, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3600Not sealed yet
Aug 2027A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisNCT07265479 · Tapinarof cream, 1%, Vehicle CreamOrganon and CoImmunology & inflammationPhase 3187Not sealed yet
Aug 2027A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal CancerNCT06614192 · Telisotuzumab AdizutecanAbbVieOncologyPhase 274Not sealed yet
Aug 2027A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabNCT06880744 · Risankizumab, Risankizumab, VedolizumabAbbVieImmunology & inflammationPhase 3573Not sealed yet
Aug 2, 2027A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionNCT05120349 · Osimertinib, PlaceboAstraZenecaOncologyPhase 3390Not sealed yet
Aug 4, 2027A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or OverweightNCT07662122 · BI 3034701, Placebo matching BI 3034701Boehringer IngelheimDiabetes & obesityPhase 2342Not sealed yet
Aug 4, 2027Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantNCT05317416 · Elranatamab, Lenalidomide, LenalidomidePfizerOncologyPhase 3854Not sealed yet
Aug 4, 2027A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932 · PF-08653945, PF-08653944, PlaceboPfizerDiabetes & obesityPhase 2940Not sealed yet
Aug 6, 2027A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee OsteoarthritisNCT04368806 · JointStem, Placebo ControlNature Cell Co. Ltd.Immunology & inflammationPhase 2/3173Not sealed yet
Aug 7, 2027A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 MutationNCT04856982 · Tofersen, PlaceboBiogenNeurologyPhase 3158Not sealed yet
Aug 9, 2027A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid AngiopathyNCT06393712 · Placebo, ALN-APPAlnylam PharmaceuticalsRare genetic diseasePhase 2210Not sealed yet
Aug 9, 2027Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell LymphomaNCT06356129 · Golcadomide, Placebo, RituximabCelgeneOncologyPhase 3850Not sealed yet
Aug 10, 2027A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)NCT06891066 · ISL, ULO, BIC/FTC/TAFMerck Sharp & Dohme LLCInfectious disease & vaccinesPhase 2150Not sealed yet
Aug 10, 2027A Study of Zigakibart in Adults With IgA NephropathyNCT05852938 · BION-1301, PlaceboNovartis PharmaceuticalsKidneyPhase 3383Not sealed yet
Aug 20, 2027A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)NCT07037771 · zodasiran Injection, PlaceboArrowhead PharmaceuticalsCardiovascularPhase 370Not sealed yet
Aug 23, 2027A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older AdultsNCT05371080 · HZ/su vaccineGlaxoSmithKlineInfectious disease & vaccinesPhase 33,038Not sealed yet
Aug 25, 2027Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06975878 · PCV21 vaccine, Vaxneuvance vaccine, Hexyon vaccineSanofiInfectious disease & vaccinesPhase 31,092Not sealed yet
Aug 25, 2027A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252 · Maridebart cafraglutide, PlaceboAmgenDiabetes & obesityPhase 2180Not sealed yet
Aug 27, 2027Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)NCT04199689 · 9vHPV Vaccine, Placebo (Saline for Injection)Merck Sharp & Dohme LLCInfectious disease & vaccinesPhase 36,033Not sealed yet
Aug 31, 2027A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943 · CTX-009, PaclitaxelCompass TherapeuticsOncologyPhase 2/3168Not sealed yet
Aug 31, 2027ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsNCT05671510 · Gotistobart, DocetaxelOncoC4, Inc.OncologyPhase 3630Not sealed yet
Aug 31, 2027MHB018A Treatment in Patients With Chronic Thyroid Eye DiseaseNCT07257185 · MHB018A injection, MHB018A injection PlaceboMinghui Pharmaceutical (Hangzhou) LtdOphthalmologyPhase 3150Not sealed yet
Sep 2027A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisNCT06754462 · IMVT-1402, PlaceboImmunovant Sciences GmbHImmunology & inflammationPhase 2120Not sealed yet
Sep 2027Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) DeficiencyNCT05345171 · DTX301, Placebo, Oral CorticosteroidsUltragenyx Pharmaceutical IncOtherPhase 337Not sealed yet
Sep 2027A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerNCT05608044 · Botensilimab, Balstilimab, Standard of CareAgenus Inc.OncologyPhase 2234Not sealed yet
Sep 2027A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433NCT03345823 · Upadacitinib, Placebo for UpadacitinibAbbVieImmunology & inflammationPhase 3747Not sealed yet
Sep 2027Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)NCT05775848 · BBP-418 (ribitol), PlaceboML Bio Solutions, Inc.OtherPhase 3112Not sealed yet
Sep 2027A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · Orforglipron, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3487Not sealed yet
Sep 2027A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · Orforglipron, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3487Not sealed yet
Sep 2027A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative ColitisNCT06257875 · Lutikizumab, Lutikizumab, AdalimumabAbbVieImmunology & inflammationPhase 2156Not sealed yet
Sep 2027A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)NCT06966479 · Verekitug, PlaceboUpstream Bio Inc.RespiratoryPhase 2396Not sealed yet
Sep 2027A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaNCT06679985 · Casdozokitug, Toripalimab, BevacizumabCoherus Oncology, Inc.OncologyPhase 272Not sealed yet
Sep 2027A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic AsthmaNCT06653322 · HR-1703, PlaceboGuangdong Hengrui Pharmaceutical Co., LtdRespiratoryPhase 3401Not sealed yet
Sep 2027A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 · Retatrutide, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3586Not sealed yet
Sep 2027A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · Orforglipron, PlaceboEli Lilly and CompanyDiabetes & obesityPhase 3974Not sealed yet
Sep 1, 2027REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 · Cagrilintide, Semaglutide, PlaceboNovo Nordisk A/SCardiovascularPhase 37,101Not sealed yet
Sep 3, 2027Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686 · Maridebart cafraglutide, PlaceboAmgenDiabetes & obesityPhase 3250Not sealed yet
Sep 10, 2027Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeNCT06824181 · PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccineSanofiInfectious disease & vaccinesPhase 3580Not sealed yet
Sep 12, 2027A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerNCT06764485 · BMS-986365, Enzalutamide, AbirateroneCelgeneOncologyPhase 3960Not sealed yet
Sep 20, 2027A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585 · Dato-DXd, Durvalumab, CapecitabineAstraZenecaOncologyPhase 31,174Not sealed yet
Sep 21, 2027Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisNCT05126277 · ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.Novartis PharmaceuticalsKidneyPhase 3452Not sealed yet
Sep 21, 2027Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityNCT07311850 · MET097, PlaceboPfizerDiabetes & obesityPhase 33,578Not sealed yet
Sep 24, 2027Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative ColitisNCT03221036 · Vedolizumab IV, PlaceboTakedaImmunology & inflammationPhase 3392Not sealed yet
Sep 28, 2027A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT05785767 · fianlimab, cemiplimab, PlaceboRegeneron PharmaceuticalsOncologyPhase 2/3149Not sealed yet
Sep 28, 2027Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)NCT06456346 · Bomedemstat, Hydroxyurea, Bomedemstat placeboMerck Sharp & Dohme LLCCardiovascularPhase 3300Not sealed yet

Forecasts are research. They are not medical advice or investment advice.